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5The European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) has great pleasure in presenting
its sixth Annual report on the state of the drugs
problem in the European Union. The main purpose of
the report is to help guide policy-making at EU,
national and regional level.
This report presents an up-to-date picture of the drug
situation in the EU and highlights new trends and devel-
opments. In addition to the general overview, the report
addresses some key issues — cocaine, infectious diseases
and synthetic drugs — in more detail. It also provides a
general overview of the situation in the central and east
European countries.
This year, the improvement in the quality and compa-
rability of data produced by Member States is significant.
Nevertheless, it is essential to maintain efforts in all
Member States not only to enhance the comparability of
data at EU level in all areas but also to ensure that these
data are produced regularly.
This leads us to the very important issue of harmonising
data which must be rapidly achieved to ensure that the
information on drugs at EU level becomes more reliable
and comparable than it is now. To facilitate this process,
the EMCCDA has produced guidelines for the standard-
ised implementation in the EU of its five key epidemio-
logical indicators. In the coming year, the Member States
will play a key role in ensuring the full implementation of
these standardised indicators at national level.
It is of particular note that the EU strategy on drugs and its
follow-up action plan (2000–04) highlight information
and evaluation as key priorities. Indeed, collecting and
analysing information forms a preliminary step in assess-
ing the impact of any action. The EU action plan also
emphasises the importance of drawing on the different
sources of information available in the European Union
— in particular the EMCDDA and Europol. 
The EMCDDA is working intensively to fulfil its key
information role. It has fine tuned its 2001–03 work
programme to align it with the six priority targets of the
EU strategy on drugs. The Centre is also contributing to
the process of evaluating the impact of the EU action
plan and has worked with its national focal points and
with Europol and its national drugs units to conceive
appropriate tools for producing two snapshots composed
of a set of variables adapted to the six priority targets of
the EU strategy.
The first snapshot will show the situation and responses in
place in 1999 prior to the adoption of the EU action plan
and will provide a baseline against which the progress
achieved at the end of the plan in 2004 can be measured.
The second snapshot will show the situation and
responses in place in 2004 on the basis of information
available from the same set of variables. 
All of these steps will go some way to fulfilling the
EMCDDA’s main challenge — that of providing policy-
makers with a solid knowledge base for informed drug-
policy planning.  
Georges Estievenart
Executive Director
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7Drug demand 
and drug supply
This chapter provides an overview of the situation of EU drug use and supply and
highlights recent developments and emerging trends.
1C h a p t e r
Improving the comparability of data — the EMCDDA key indicators
Improving the comparability of data across the Member
States is acentral taskof theEMCDDA.TheEMCDDAdevel-
ops and recommends methods and instruments in order to
collect and analyse harmonised, good quality data at
European level. The EU action plan on drugs (2000–04)
calls forMemberStates toprovide reliableandcomparable
informationonfivekeyepidemiological indicators accord-
ing to the EMCDDA’s recommended technical tools and
guidelines.Thesefivekey indicatorsare:
• prevalence and patterns of drug use among the
general population (population surveys);
• prevalence and patterns of problem drug use (statisti-
cal estimates of prevalence/incidence supplemented
by surveys among drug users);
• drug-related infectious diseases (prevalence and
incidence rates of HIV, hepatitis B and C in injecting
drug users);
• drug-related deaths and mortality of drug users
(general population mortality registers and special
registers statistics, and cohort studies among drug
users of mortality and causes of death);
• demand for drug treatment (statistics from drug treat-
ment centres on clients entering treatment).
(1) Figure 1 OL: Lifetime experience of cannabis, amphetamines and cocaine among adults in some EU countries, measured by
national population surveys (online version).
Drug use
Drug use in the general population
An estimation of the proportion of the population that uses
drugs, or that has experimented with them, is basic infor-
mation to assess the drug situation, to develop policies
and to evaluate them. It is necessary to know in which
groups drug use is concentrated and the patterns of use.
Patterns of drug use
In all EU countries, cannabis is the illegal substance most
commonly used, both in terms of lifetime experience (any
use during a person’s lifetime) and in recent use. Use of
other illegal substances is less common.
Cannabis lifetime experience in the adult population (15
to 64 years according to the EMCDDA standard, although
with some national differences) ranges from about 10 %
in Finland to about 20 to 25 % in Denmark, France,
Ireland, the Netherlands, Spain and the United
Kingdom (1).
Other substances have been experienced by far fewer
persons. Experience with amphetamines is reported by 1
to 4 % of adults, but by up to 10 % in the United
Kingdom. Ecstasy has been tried by 0.5 to 4 % of
European adults and cocaine by 0.5 to 3 %. Heroin
experience is reported generally by less than 1 % of
adults, which contrasts with its high presence in drug-
problem indicators.
Illegal drug use is concentrated in some groups of the
population — in particular young adults, males and
urban inhabitants. Young adults (aged 15 to 34 according
to the EMCDDA standard with some national differences)
2001 Annual report on the state of the drugs problem in the European Union
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present rates up to double or more than those of the
whole adult population for most drugs (2) (3).
For example, cannabis has been tried by about 15 % of
young adults in Finland and Sweden, up to about 28 to
40 % in Denmark, France, Ireland, the Netherlands,
Spain and the United Kingdom, while amphetamines,
ecstasy and cocaine have been tried by about 1 to 6 % of
young adults (although in the United Kingdom figures for
amphetamine and ecstasy are around 16 and 8 %
respectively). Higher rates of drug use are evident among
males, although this varies across countries and differ-
ences tend to decrease over time (4).
Inhabitants of urban areas report higher rates of drug use
than those of rural areas, and differences in overall
national figures could be largely conditioned by the
proportion of urban population (5).
Although widely used, lifetime experience is insufficient
to estimate recent drug use since it includes all those who
have ever tried drugs, whether once or years ago. Recent
use is usually estimated as any use during the previous
year (last-12-months prevalence).
Recent use (expressed as last-12-months use) of cannabis
is reported by 1 to 9 % of European adults. Recent use of
other illegal substances rarely exceeds 1 % among adults.
Young adults report higher prevalence figures, roughly
double that for all adults. In Ireland, Spain (for cocaine)
and the United Kingdom figures tend to be somewhat
higher than in other countries (6).
Trends
Information on drug trends can be more informative than
a fixed picture. However, until now only Germany, Spain,
Sweden and the United Kingdom have carried out series
of comparable, national surveys. Other countries
conducted several different surveys and trends have to be
analysed with caution.
Lifetime experience of cannabis increased over the 1990s
in most countries where information is available. In recent
surveys, many countries report relatively similar preva-
lence figures — roughly 20 to 25 %. Where prevalence
was low early in the 1990s (for example, in Greece,
Finland and Sweden), increases seem to have been propor-
tionally greater than where initial prevalence was higher
(for example, in Denmark, Germany and the United
Kingdom).
Methods employed to estimate drug use in the general population
General population surveys are employed to estimate
drug use. Twelve Member States have conducted national
surveys during recent years on drug use in the general
population (although in Luxembourg the sample was
small) and the remaining ones (Italy, Portugal and Austria)
are currently organising them. Several countries have
already established series of repeated national surveys
using the same methodology (for example Germany,
Spain, Sweden and the United Kingdom) and in Greece,
France and the Netherlands series have been initiated.
Some countries have successive ad hoc surveys which are
comparable to some extent (for example Denmark,
Finland and France).
There are differences across countries in methods of data
collection, sampling sizes and frames, which could influ-
ence the precision and validity of estimates. Until these
issues are solved, direct comparisons between levels of
use in Member States should be made with caution,
especially where differences are small.
The EMCDDA has developed guidelines to improve
quality and comparability of population surveys in the
EU. These guidelines include a set of common core items
that can be used to report data from existing surveys or
that can be inserted into broader questionnaires and basic
methodological guidelines, and they are gradually being
implemented in the Member States. 
(2) Figure 2 OL: Last-12-months prevalence of ecstasy and cocaine by age group in England and Wales, 1998 (online version).
(3) Figure 3 OL: Lifetime experience of cannabis among all adults and among young adults in some EU countries, measured by
national population surveys (online version).
(4) Figure 4 OL: Lifetime experience of cannabis among adults (males and females) in some EU countries, measured by national
population surveys (online version).
(5) Figure 5 OL: Lifetime experience of cannabis among adults in Finland by level of urbanisation, 1998 (online version).
(6) Figure 6 OL: Lifetime experience and last-12-months prevalence of cannabis among adults in some EU countries, measured by
national population surveys (online version).
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Drug use in the school population
For under-18-year-olds, the EMCDDA draws on informa-
tion from a comparable schools survey which includes
data from 30 participating countries in Europe and also
data from the United States. Eleven EU Member States
participated in the most recent 1999 European School
survey project (ESPAD) (1), which describes tobacco,
alcohol and other drug use among 15 to 16-year-old
students. Belgium, Luxembourg, and Spain also
conducted school surveys in 1998 or 1999 independently
from the ESPAD survey and the results from these are
consistent with those from ESPAD. 
Situation and patterns
These surveys show that cannabis continues to be the
most widely used illegal substance among school
students. Lifetime experience among 15 to 16-year-old
students ranges from 8 % in Sweden and Portugal to 
35 % in France and the United Kingdom. In two Member
States (Greece and Sweden), lifetime use of inhalants
(volatile substances) is higher than, or equals, that of
cannabis.
School surveys report lifetime use of amphetamine by 1
to 8 % of 15 to 16-year-old school students, ecstasy use
by 1 to 5 %, and figures for lifetime use of cocaine are
between 1 and 4 %, with Spain and the Netherlands at
the higher end of cocaine use.
A different pattern occurs in illicit lifetime use of tranquil-
lisers and sedatives (without a doctor’s prescription)
where the United Kingdom and Norway, at 4 %, are at
the lowest end of illicit lifetime experience and France at
the highest (12 %). Illicit lifetime use of tranquillisers and
sedatives is higher amongst girls than boys in France,
Portugal, Italy, Finland, and Sweden. In contrast, lifetime
prevalence for illegal drugs is higher amongst boys than
girls in all Member States.
It is worth noting that comparable data from the United
States show that figures for lifetime use of a number of
illegal drugs are higher than in any of the EU Member
States: cannabis (41 %), amphetamine (16 %), ecstasy 
(6 %) and cocaine (8 %).
There is a negative relationship between the prevalence
rate of illegal drug use in a country and the perceived risk
attributed to that particular drug, and girls are generally
more apt than boys to consider illegal drug use a risk.
Disapproval of illegal drug use is consistently high among
boys and girls in all the EU Member States at around
80 % on average, excluding disapproval of cannabis,
which is lower at 70 % average.
Trends
In all except two of the Member States (United Kingdom
and Ireland) that participated in both the early and later
ESPAD surveys, the lifetime prevalence of all illegal drug
use increased between 1995 and 1999.
Lifetime use of cannabis
Figures of illegal drug taking in general by 15 to 16-year-
old school students are largely determined by cannabis
figures. In the majority of countries the prevalence of
lifetime cannabis has increased. 
In Finland and Norway, lifetime use of cannabis figures
doubled between 1995 and 1999. Increases also occurred
in Sweden, Portugal, Denmark and Italy. However, there
was a decrease in the two Member States which had the
highest lifetime prevalence of cannabis in 1995. In the
United Kingdom, between 1995 and 1999 it decreased
from 41 to 35 % and in Ireland from 37 to 32 %.
Perceived availability of cannabis increased substantially
in Denmark, Finland, Italy and Norway between 1995
and 1999. In Ireland and the United Kingdom, there were
decreases in the perceived availability of cannabis but the
decrease is less than the decrease in lifetime prevalence.
Lifetime use of ‘other illicit drugs’ (amphetamine,
LSD/hallucinogen, crack, cocaine, ecstasy and heroin)
The ESPAD survey also shows an increase in lifetime use
of collapsed categories of ‘other illicit drugs’ in the major-
ity of Member States but a sharp decline in the United
Kingdom and Ireland, where it fell from 22 to 12 % and
from 16 to 9 % respectively. Increases in the majority of
Member States and declines in the United Kingdom and
Ireland confirm the trend towards convergence in
patterns of drug use among the Member States. The
substantial decrease in Ireland and the United Kingdom
may imply that in advanced stages of drug diffusion the
pool of 15 to 16-year-olds willing to experiment with
illegal drugs is becoming saturated.
Lifetime use of tranquillisers or sedatives without a
doctor’s prescription
Traditionally, use of tranquillisers or sedatives without a
doctor’s prescription has been considerably higher
amongst girls than boys. Between 1995 and 1999, girls in
Denmark, Italy, Ireland, and the United Kingdom showed
substantial decreases of around a half in the figures for
lifetime prevalence of tranquillisers and sedatives without
a doctor’s prescription. In contrast, girls in Finland and
Portugal showed increases (3 % and 2 % respectively),
whilst boys in these two countries showed decreases.
Lifetime use of inhalants
There was little change in lifetime use of inhalants except
in Sweden and the United Kingdom where there was a
decrease between 1995 and 1999. 
(1) The 1999 ESPAD report: ‘Alcohol and other drug use among
students in 30 European countries’, B. Hibbell, B. Andersson,
S. Ahlström, O. Balakireva, T. Bjarnson, A. Kokkevi, M.
Morgan, the Swedish Council for Information on Alcohol
and Other Drugs (CAN), the Pompidou Group of the Council
of Europe, December 2000.
2001 Annual report on the state of the drugs problem in the European Union
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Problem drug use
In general, prevalence rates of problem drug use seem to be
highest in Italy, Luxembourg, Portugal and the United
Kingdom, with between five and eight problem drug users
per 1 000 inhabitants aged 15 to 64 (this is taking the
midpoints of the range within a country). Rates seem lowest
in Belgium (but this data refers only to IDUs and thus is an
underestimate), Germany and the Netherlands, with two
to threeproblemdrugusersper1000 inhabitants aged15 to
64. Intermediate rates range from between three and five
problem drug users per 1 000 inhabitants aged 15 to 64 in
Austria, Denmark, Finland, France, Ireland, Spain and
Norway. Some countries report slightly different figures
than in 2000 due to improved data and estimates. Denmark
and especially Finland, however, have much higher figures
owing to having suppressed less reliable (and in both cases
lower) estimates.
NB: Data are from the most recent national surveys available in each country.
The age range is from 15 to 18 until 34 to 39. Variations in age ranges may partially influence disparities between countries. In some countries the figures were recalculated, at national level, to 
adapt as far as possible to standard EMCDDA age groups (young adults 15–34).
Sources: Reitox national reports 2000, taken from population surveys reports or scientific articles. See also standard epidemiological tables on the EMCDDA web site.
Recent use (last-12-months prevalence) of cannabis, amphetamines and cocaine among young adults in some EU countries,
measured by national population surveys
Fig. 1
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NB: The age range is from 15 to 18 years to 59 to 69 years (in Finland, it was 74 in 1992 and 1996). Variations in age ranges may partially influence disparities between countries.
In Denmark, the age range is 16–44 in order to compare between years, but figures should not be compared with other countries.
In Germany, results from a 2000 survey (published in May 2001) show an increase in cannabis use.
Samples have to be large enough and the analysis focused on appropriate age groups. Oversampling of young people should also be considered.
Sources: Reitox national reports 2000, taken from survey reports or scientific articles. See also standard epidemiological tables on the EMCDDA web site.
Evolution of lifetime experience and recent use (last-12-months prevalence) of cannabis among adults in some EU countries during the 1990s,
measured by population surveys
Fig. 2
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Lifetime experience
Last-12-months prevalence
Increased lifetime experience of cannabis does not
necessarily imply a parallel growth in recent use. Last-
12-months prevalence has generally risen less than
lifetime experience.
Trends in the use of other substances are more difficult to
track. These developments tend to involve relatively
limited groups of the population, but nevertheless they
can have important implications on public health and
drug policy. For example, the much-discussed possible
increase in cocaine use still needs to be analysed in more
detail in most countries. Also, recent increase in ecstasy
use — well documented among groups of young people
— does not show up clearly in population surveys cover-
ing the whole population. Samples have to be large
enough and the analysis focused on appropriate age
groups. Oversampling of young people should also be
considered.
Drug demand and drug supply
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An EMCDDA project produced new incidence estimates
of heroin use for Belgium, Lisbon, Budapest, London and
Amsterdam suggesting that the timing of heroin
epidemics in those regions may have been very different
(see Figure 4, London and Amsterdam not shown).
Figure 5 shows how, even within one country, in this case
Italy, heroin epidemics may occur in different regions at
different moments. The results also suggest that there
might be an initial (epidemic) period of rapid spread
followed by saturation effects (that is most susceptible
persons have become heroin users) and lower but
constant further spread (endemic situation) — a mecha-
nism which is similar to the spread of infectious diseases.
This may have important implications for decision-
makers as regards the optimal balance between policy
measures such as primary prevention, which needs to be
timely to prevent high prevalence, and secondary preven-
tion (drugs treatment and harm-reduction measures),
which becomes more important once high prevalence
has been established.
Definition and methods used to estimate problem drug use
‘Problem drug use’ is defined here as ‘injecting drug use
or long-duration/regular use of opiates, cocaine and/or
amphetamines’. This definition excludes ecstasy and
cannabis users and those who never — or irregularly —
use opiates, cocaine or amphetamines. Opiates include
prescribed opiates such as methadone. The national
estimates of problem drug use reported here for the EU
and Norway (which also participated in the EMCDDA
project on prevalence estimation) are for 1996 to 1998.
Austria (1995) and Belgium (1995) could not provide
estimates for this time period, due to lack of more recent
data on which to base the calculations (see Figure 3),
while Luxembourg, Portugal and Italy provided more
recent ones (1999–2000).
The methods used to produce these estimates are mainly
based on statistical models incorporating drug-related
indicators and include:
• the multivariate indicator method;
• capture–recapture;
• three multiplier methods based on police data, treat-
ment data and mortality rates; and
• a multiplier method using back-calculated numbers of
intravenous drug users (IDUs) with HIV/AIDS, in
combination with HIV/AIDS rates among IDUs.
The ranges given in Figure 3 are often derived from a
multiple method approach; therefore the lowest and
highest figures may have been obtained by different
methods, both within and between countries. These
methods do not always refer to the same target group —
for example, HIV/AIDS back calculation and overdose
mortality multipliers target IDUs, while multipliers from
treatment data could only be used for the wider group of
problem opiate users.
Several countries applied multiple estimation methods —
two (Spain, Luxembourg and the Netherlands), three
(Germany, France, Ireland, Finland and the United
Kingdom) or even four (Italy and Portugal). Other
countries (Belgium, Denmark, Austria, Sweden and
Norway) could only apply one method, while Greece
was still unable to provide an estimate. Using multiple
independent estimates may cross-validate the single
figures and lead to a more reliable overall estimate for a
country. Therefore, a multiple method approach, if possi-
ble on a year-by-year basis, may ideally be applied. 
Besides estimates of prevalence, data on patterns of use
are important. However, there are little data on patterns
of drug use among problem drug users who are not in
treatment, although this is important information for
guiding policy decisions on future treatment demand. In
northern countries, notably Finland and Sweden, primary
amphetamine users form the majority of problem drug
users (an estimated 70 to 80 % in Finland in 1997). This
is contrary to other countries where problem drug users
are mostly primary opiate users (but often polydrug
users). 
Trends
Although important for policy evaluation, it is still not
possible to calculate trends in the prevalence of problem
drug use with the current methods, data quality and data
availability. Incidence of problem drug use may be an
additional and important way of measuring trends.
Incidence is the number of newly occurring cases in a
year, while prevalence is the total of all existing cases,
new and old. Therefore trends in incidence are much
more sensitive to epidemiological changes and to inter-
ventions that prevent new cases from occurring.
2001 Annual report on the state of the drugs problem in the European Union
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In Figure 5, it is notable that the heroin epidemic in
Puglia seems to have started earlier than in Sicilia and
Campania. Puglia, the ‘heel’ of Italy, is situated on an
important heroin trade route from the Balkan region
into Europe, which may have led to earlier spread of
heroin use. This confirms earlier results based on
geographical analysis of treatment data (2000 annual
report, EMCDDA).
Differences in the prevalence of drug use are influenced
by a variety of factors in each country. As countries with
more liberal drug policies (such as the Netherlands) and
those with a more restrictive approach (such as Sweden)
have not very different prevalence rates, the impact of
national drug policies (more liberal versus more restrictive
approaches) on the prevalence of drug use and especially
problem drug use remains unclear. However, comprehen-
sive national drug policies are of high importance in
reducing adverse consequences of problem drug use such
as HIV infections, hepatitis B and C and overdose deaths.
Other factors that may affect prevalence of problem drug
use are the availability and price of drugs, unemployment
and poverty or other societal problems (war), the age
structure of a country and the proportion of urban and
Fig. 3 National prevalence estimates of problem drug use 
in the EU and Norway, 1996–98
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NB: n.a. = data not available.
Differences between countries have to be interpreted with caution due to
different methods and target groups. For more detail, see online Tables 
1OL and 2OL at www.emcdda.org. Data for Austria and Belgium are for
1995, Italy for 1999 and Portugal for 1999–2000. The original Swedish
estimate has been reduced by 8 % to exclude cannabis addicts, compatible
with EMCDDA definition of problem drug use. Colour for a country
indicates the midpoint of the range in estimates, except for Belgium (point
estimate 3.0 and 95 % confidence interval). The Belgian estimate refers to
IDUs and thus underestimates total problem drug use.
Sources: Reitox national focal points, 2000. For Sweden:  B. Olsson, C.A. Wahren, S.
Bygvist, Det tunga narkotikamissbrukets, omfattning i Sverige 1998, CAN,
Stockholm, 2001. 
NB: Relative incidence is the incidence (number of new users per year) of opiate users who
will eventually go to services. Lisbon: extremely problematic area of Lisbon, users
presenting themselves to social services. Belgium: sample going for treatment in
French Community.
Source: EMCDDA project CT99.EP.05, ’Study on incidence of problem drug use and latency time
to treatment in the European Union’, Lisbon 2001 (coordinated by University Rome ’Tor
Vergata’).
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opiate users who eventually went for treatment or to social
services, for Belgium, Lisbon and Budapest — estimated by
the Brookmeyer and Liao method
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will eventually go to services.
Source: EMCDDA project CT99.EP.06, ’Study on incidence of problem drug use and latency time
to treatment in the European Union’, Lisbon 2001 (coordinated by University Rome ’Tor
Vergata’).
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rural areas. Furthermore, drug use seems to behave in an
epidemic manner (see for example Figures 4 and 5). It
may thus follow long-term epidemic cycles that for a large
part depend on the demographic replenishment of new
generations of ‘susceptible‘ young people, who have
never experienced the problems associated with heavier
patterns of use. At present, therefore, a final causal inter-
pretation of varying prevalence rates within EU Member
States cannot be made.
Additional qualitative or local information on trends
in problem drug use is available for some countries
or cities.
In Austria, problem drug use prevalence seems currently
stable in most regions, although in Vienna street workers
have registered a decline in the number of young
newcomers on the scene. In France, heroin consumption
is in general declining although it is not clear what this
means in terms of numbers of heroin users and there are
some indications of new, local increases. In Finland,
prevalence estimates for the greater Helsinki area for
Benelux
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1995–97 suggest that the use of hard drugs has
increased in this area by a minimum of 40 % in two
years. This increase was most pronounced in males,
those over 26 years old and in amphetamine users.
In Germany, heroin use is primarily found in metropoli-
tan areas, prevalence rates and seizures in rural areas
being much lower. In the new Länder, heroin use is still
scarce. Surveys suggest that heroin use is only slightly
increasing or stagnating since 1992; however, cocaine
shows stable and uniform growth. In Greece, data from
indirect indicators (treatment, deaths, low-threshold
services) suggest that problem drug use is increasing. In
Ireland, drug users are young reflecting the general
demographic situation. Until about 1996, the trend in
heroin use was towards increased smoking; however,
more recently, injecting is again increasing. In Italy, drug
use levels seem higher in northern regions but problem
drug use may be more evenly distributed between north-
ern, central and southern regions even if the level of ‘at
risk’ population is different between geographical areas.
(The total population of 15–54-year olds is around 32
million — 44 % live in the northern regions, 19 % in
the central regions and 37 % in the southern regions.)
In addition, northern regions may have relatively more
use of ‘recreational drugs’.
In Luxembourg, the national registration system showed
a marked increase of 42 % of new registrations
between 1998 and 1999, however this is mainly due to
drug law offenders and may reflect policing activity.
There is a large proportion of non-natives from
Luxembourg (48 %) among problem users. The
estimated prevalence shows an upward trend; while
injecting drug use has decreased from over 90 % to
about 66 %. In Amsterdam, the Netherlands, the
number of heroin users has moderately decreased over
the years, while the proportion of injectors among
them has strongly decreased. In Portugal, drug use
problems are more significant in the districts of Lisbon,
Porto, Setubal and Faro. In Spain, heroin use, especially
injected, is becoming less relevant and cocaine
problems are becoming more important among drug
problems. In Sweden, there has been an increase in the
number of severe drug users during the 1990s and
heroin use is becoming more common in younger
groups of problem users. In the United Kingdom, a
report published in 1998 suggested an increase of new
heroin outbreaks among young people in most regions
of England since about 1996, while a recent study in
London suggested a two-fold increase in incidence of
non-injected heroin use between 1991 and 1997.
Health consequences of drug use
Demand for treatment
Characteristics of clients entering treatment (such as
social characteristics) and consumption behaviours (such
as the proportion of injectors or opiate users) are potential
indicators of wider trends in problem drug use. However,
biases may arise owing to different methods of collecting
the information and differences in the offer of treatment
services between countries.
Substances
Despite differences in treatment policies and recording
practices, it is possible to identify both common and
particular trends across Europe.
In most countries, opiates are the main drug for new
clients entering treatment (especially heroin). The varia-
tion between countries is quite high — from 22.4 % in
Finland to 84.2 % in Greece, but the most frequent
percentages are between 50 and 70 %. Apart from
heroin, other main substances for which treatment is
sought are cannabis (over 15 % in Belgium, Denmark,
Finland and Ireland) and cocaine (especially the
Netherlands at 15.4 % and Spain at 17 %). Ecstasy is the
main drug only in a low number of cases, the highest
value being 8.9 % in Ireland. Strong differences exist
concerning amphetamines, the highest percentages being
reported from Finland (39 %), Sweden (17 %) and
Belgium (15 %). 
Trends
Common trends are identified in the number of new
clients seeking treatment — new clients demanding treat-
ment for heroin are decreasing while they are increasing
for cannabis and especially cocaine use. The highest
increase in cannabis clients regards Germany (from
16.7 % in 1996 to 40 % in 1999 although it is important
to note that this data only refers to outpatient units) and
Ireland (from 20.7 % in 1996 to 29.4 % in 1999) and
Denmark (from 25 % in 1996 to 31 % in 1999), whilst
the biggest rise in cocaine users is reported by Spain
(from 21.6 % in 1998 to 30.9 % in 1999) and the
Netherlands (from 14.7 % in 1994 to 23.2 % in 1999).
These trends are confirmed by data of all clients admit-
ted to treatment over the years, where the increase in
cocaine users is clear, as well as in the comparison
between new and all clients admitted to treatment in
some Member States. Furthermore, an increase in
cocaine use as a secondary drug is shown in clients
using opiates as a main substance (7) (8). In general,
(7) Figure 7 OL: Trends for all clients admitted to treatment for heroin, cannabis and cocaine (online version). 
(8) Figure 8 OL: All and new clients admitted to treatment for cannabis and cocaine use, 1999 data (online version). 
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(1) Austria, Portugal and France are not included because of non-comparable reporting systems.
(2) Belgium (1998 data): heroin includes all the opiates and amphetamines all the stimulants.
(3) Germany: heroin includes all the opiates.
(4) Italy: also includes clients still in treatment from the previous year.
(5) Sweden: heroin includes all the opiates.
Sources: Reitox national reports 2000.
All clients admitted to treatment for heroin, cannabis, amphetamines, cocaine
and other substances in some Member States (1)
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clients demanding treatment use more than one drug
and differences are identified in single user groups.
An increase in the demand for substitution treatment is
reported in many countries, especially by pregnant
women; it is probably due to these services being more
widely available.
Injecting drug use and other routes of administration
The proportion of injectors among clients in treatment for
heroin varies markedly, from 12.5 % of injectors in the
Netherlands to 72.7 % in Greece. A general decrease in
injecting heroin is quite common in most countries, even
if variable (Ireland reports a contrary increasing trend in
injecting drugs). A comparison between all and new
clients demanding treatment for heroin seems to confirm
the decrease in injecting heroin (an average of about
10 % fewer inject heroin) (9).
Many factors could influence the ways of administration
and these are still not really clear or demonstrated by
scientific studies, but could include market factors,
cultural traditions and interventions.
At market level three main factors could influence the
route of administration: the relative availability of smoke-
able heroin (base form) or injecting (hydrochloride)
heroin, heroin price (a higher price leads to more inject-
ing), heroin purity (lower purity is related to a higher level
of injecting use).
From a cultural point of view, there are some tradi-
tions especially linked to ethnic minorities; within the
Suriname’s subgroup, aversion to injecting seems to have
influenced the route of administration (sniffing or
smoking) used by heroin consumers. The same influence
was not found in other subgroups such as North
African consumers in France or Antilleans, who also
traditionally smoke or sniff heroin.
Various evaluation studies also highlight the relation
between prevention activities (facilities, information on
(9) Figure 9 OL: Proportion of injectors among all and new clients admitted to treatment for heroin use in some Member States, 1999
data (online version).
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Possible increases in HIV transmission among IDUs in some EU countries
Preliminary data suggest that increases in HIV infection
may have occurred among subgroups of IDUs in some EU
countries.The limitations of using routine data for detecting
changes in transmission should be taken into account (see
Chapter 3 page 37). For example, the increase in Ireland
may partly be due to increased testing of IDUs. However, it
is important to carefully monitor these possible increases
and take appropriate action if necessary. Increases in HIV
transmission may have occurred inAustria, Luxembourg,
Ireland, the Netherlands, Portugal and Finland.
In Austria, HIV prevalence among opiate overdoses
increased to 5 % in 1999 (from 3 % in 1996, 2 % in
1997 and 1 % in 1998).
In Luxembourg, notified HIV infections in IDUs rose,
from 2–3 per year in 1995–97 to 6–7 per year in 1998
and 1999.
In Ireland, the number of IDU-related HIV positive tests
tripled to 69 in 1999 (from 20–26 per year in the period
1994–98). 
In Portugal data are from local sources. In Coimbra,
prevalence among IDUs in treatment increased from 9 to
13% between 1999 and 2000, while this was mainly
among females and from 9.5 to 18 % in the age group
25–34. A street-based study among 250 homeless heroin
users in a very problematic area in Lisbon found a preva-
lence of 48 % in 1998–99. 
In Finland, a large increase in IDU-related HIV notifica-
tions occurred from 0–5 yearly cases during 1990–97, to
20 cases in 1998 and 84 cases in 1999. Prevalence
among needle exchange attendees asking for an HIV test
also increased, from 0 % in 1997 to 3 % in 1998, 8 %
in 1999 and decreased back to 3 % in 2000. 
In the Netherlands, HIV infection rose from 11 to 22 %
between 1994 and 1998/99 among IDUs in the city of
Heerlen, southern Netherlands.
NB: Sample sizes: Austria 1996 — 184, 1997 — 131, 1998 — 108,
1999 — 126; Netherlands Heerlen 1994 — 161, 1998/1999 —
116; Portugal Coimbra 1999 — 227, 2000 — 106, Lisbon
1998/1999 — 252; Finland 1997 — 131, 1998 — 135, 
1999 — 63, 2000 — 356.
Sources: National focal points. For Lisbon data: H. Valle, L. Rodrigues, 
R. Coutinho, et al., HIV, HCV and HBV infection in a group of
drug addicts from Lisbon, Seventh European Conference on
Clinical Aspects of HIV infection, 23–27 October 1999, Lisbon,
Portugal (abstract 866).
the risks of injecting) and changes in attitudes from inject-
ing to sniffing or smoking as an influencing factor.
Social characteristics
Clients entering treatment tend to be males in their 20s
or 30s.Themeanage is29years forall clientsand27 fornew
clients.Thewomenareusuallyyounger thanmen,demand-
ing treatmentalmostayearbeforemen.Theoldestclientsare
in Sweden and the Netherlands, whilst the youngest are in
IrelandandFinland,although in thecaseof Ireland thisalso
reflects thedemographicsituation in thecountry.
The gender distribution varies with a similarity among
southern countries, where men are the largest majority
(86/14 in Italy, 85/15 in Spain, 84/16 in Portugal, 84/16 in
Greece) and among northern countries with a higher
presence of women in treatment (70/30 in Ireland, 72/28
in Sweden).
The social conditions of clients demanding treatment
seem to be worsening, in terms of level of education and
employment. The majority of clients are concentrated in
urban areas, but this could also be due to a different level
of services provision in rural areas.
Drug-related infectious diseases
Amoredetailed insight into this issue isprovided inChapter
3, Selected issues—Drug-related infectiousdiseases.
Prevalence and trends
As available data are from different sources (sometimes
local), only a general impression of HIV prevalence in
injecting drug users (IDUs) can be given. However, large
differences are apparent between, as well as within,
countries. Availabledata indicate levelsof infectionamong
different subgroups of IDUs that roughly vary from about
1 % in the United Kingdom to 32 % in Spain.This overall
picture has not changed in recent years. However, there are
indications of new increases of HIV transmission in
(subgroupsof) IDUs in somecountries (seeboxabove).
Data on prevalence of infection with hepatitis C virus
(HCV) are less available and, where available, are subject
to the same limitations as the HIV data. However, the
overall picture is clear — HCV prevalence is extremely
high in the data from all countries of the EU, with infec-
tion rates of between 40 and 90 % in different subgroups
of IDUs (Figure 9). As far as they are available, data on
prevalence in IDUs aged under 25 indicate levels of HCV
infection from 20 % (Belgium, treatment, 1998) to over
2001 Annual report on the state of the drugs problem in the European Union
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depressant substances such as alcohol or benzodi-
azepines is considered a risk factor for opiate overdose.
Acute deaths with presence of cocaine, amphetamine or
ecstasy without opiates seem to be infrequent in Europe.
Many opiate deaths occur up to three hours after use,
making medical intervention possible. In addition many
fatal and non-fatal overdoses are witnessed by other users,
whichwouldmake interventionpossible—insuchcases, it
is important thatusersknowhowtoseekeffectiveassistance.
Most opiate deaths occur among injectors in their
late 20s or 30s, usually after several years of use.
The large majority of deaths occurred among males.
As with clients entering treatment, a clear ageing
trend is observed among deceased opiate users in
many EU countries (11).
Some cocaine-related deaths may pass unnoticed
because of the social background of victims or because of
a different clinical presentation of them (such as ischemic
heart diseases or arrhythmia). Emergency services person-
(38)–58
Fig. 9 Prevalence of antibodies to hepatitis C infection 
among injecting drug users in EU member states, 1996–2000
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NB: n.a. =  data not available. Data in brackets are local.
Differences between countries have to be interpreted with caution due to
different sources and in some cases local data. Colour for a country indicates
the midpoint of the range in prevalence from the different data sources. Data
for Germany, Italy and Spain are limited to HCV prevalence among IDUs who
are in treatment. The Luxembourg data are limited to IDUs in prison. UK and
Luxembourg data and the high figures for Ireland and Finland are based on
saliva tests. The data for France and the high figure for Belgium are based on
self-reported test results, which may be unreliable. The German data are for
1995, the Swedish data for 1994. For more detail and for sources see the
complementary statistical tables at www. emcdda.org.
(0.5–25.9)
Fig. 8 Prevalence of HIV infection among injecting drug users
in EU Member States, 1996–2000
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NB: Data in brackets are local.
Differences between countries have to be interpreted with caution due to
different sources and in some cases local data. Colour for a country indicates
the midpoint of the range in prevalence from the different data sources. Data
for France, Germany, Italy and Spain are limited to HIV prevalence among
IDUs in treatment and may thus not be representative of HIV prevalence
among IDUs who are not in treatment. For more detail and for sources see
the complementary statistical tables at www. emcdda.org.
74 % (Portugal, Coimbra treatment, 2000) (see Figure 27,
in Chapter 3, Selected issues, Drug-related infectious
diseases). This suggests that HCV transmission continues
at high levels in several countries, although some studies
indicate that introducing prevention measures might have
reduced transmission (United Kingdom).
Drug-related deaths and mortality of
drug users
The number of acute drug-related deaths (‘overdoses’) is
sometimes used as a simplistic way of assessing a
country’s drug situation and to draw comparisons. Drug
deaths are a source of social and political concern,
especially acute deaths among young people.
Characteristics of acute drug-related deaths
In the last five years (1994 to 1999) based on the available
information, the overall number of cases reported by EU
countries has fluctuated between 7 000 and 8 000. In the
EU, opiates continue to be present in most cases of acute
drug-related deaths — ‘overdoses’ or ‘poisonings’ (10).
The presence of other substances, such as alcohol,
benzodiazepines or cocaine is common. The presence of
(10) Figure 10 OL: Proportion of abuse of opiate and non-opiate drugs among the cases of drug-related deaths, valid percentages based
on cases with known toxicology (online version).
(11) Figure 11 OL: Proportion of people over 30 among drug-related deaths in some EU countries, 1986 and 1999 (online version).
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Methodology and definitions for drug-related deaths
In this report the focus is placed on acute drug-related
deaths (overdoses) unless stated otherwise.
Direct comparisons between countries can be mislead-
ing because the number of drug-related deaths depends
not only on the prevalence of problem drug use and the
risk patterns (such as injection) but also on national
definitions and recording methods. For instance, Portugal
has an inclusive definition whereas Sweden has recently
changed from a broad to a more restrictive definition (1).
Drug-related deaths and mortality among drug users is
one of the EMCDDA’s epidemiological key indicators. A
European standard protocol has been developed to report
cases from general mortality registries (GMR) and special
registries (SR) — forensic or police. This standard protocol
has been tested in all Member States, and active collabo-
ration is maintained with Eurostat and the World Health
Organisation (2).
Where definitions, methods and quality of reporting
remain consistent within a given country, the statistics
can indicate trends over time and, if correctly analysed
and integrated with other indicators, can be valuable in
monitoring the more extreme patterns of drug use.
Deaths indirectly associated with drug use — deaths from
AIDS, traffic accidents, violence or suicide — should also
be taken into account when assessing the overall impact
of drug abuse, but they require different sources of infor-
mation and a more research-oriented methodology.
(1) Box 1 OL: Definitions of ‘acute drug-related death’ in EU
Member States, as used in the EMCDDA annual report, and
reported in national reports (online version).
(2) Box 2 OL: Proposed EMCDDA standard to count acute drug-
related deaths — the DRD standard, Version 1.0 (online
version).
nel should be aware of this possibility. Acute deaths
related only to ecstasy seem to be rare, despite the public
concern these caused during the mid-90s in some
European countries.
Methadone has been identified in a number of drug
deaths and its role has been discussed in several
European countries. Since methadone substitution has
become quite widespread in recent years, circumstan-
tial toxicological findings of methadone are more
frequent among drug users that die due to accidents,
AIDS, etc. A few local studies suggest that some acute
deaths may be caused by methadone diverted to the
illegal market, perhaps facilitated by poorly organised
prescription services. An improvement in the organisa-
tion of methadone substitution programmes has been
recommended in some countries. Despite these
problems, research shows that substitution treatment
reduces the risks of drug-related death among
programme participants.
Trends in acute drug-related deaths
Many EU countries witnessed a marked increase of acute
drug-related deaths in the second half of the 1980s and
the early 1990s. However, in recent years, the number of
acute deaths at EU level as a whole has stabilised,
between 7 000 to 8 000 per year, and in some countries
they have even decreased.
Multiple factors probably contribute to the recent stabili-
sation of drug-related deaths. The number of problem
drug users may have stabilised and treatment data suggest
that risk practices, for example injecting, have also
decreased in some countries. In addition, treatment inter-
ventions — including substitution programmes — have
expanded in many countries and medical assistance for
overdoses may have improved.
The stabilisation is consistent with the decrease in overall
mortality (in some cases also in overdose deaths) among
cohorts of problem drug users as described below
(mortality of drug users section).
Within the overall EU trend, different national trends
are observed.
• Several countries present a general downward
trend, although with year-to-year fluctuations, for
example, Austria, France, Germany, Luxembourg,
Italy and Spain. Austria (1999), Germany (1999–
2000) and Luxembourg (1997–98) reported new
increases recently but they are not as high as
previous values. This development has to be
closely monitored.
• Some countries have reported a substantial upward
trend until recently — for example, Greece, Ireland
(a decrease observed in 1999) and Portugal. These
NB: These trends can be calculated for all EU countries. A few are presented as examples.
Proportional variations over 1985 figures are presented. For Greece, the series begins
in 1986 to avoid distortion.
In some countries with an increasing trend, improved reporting may account for part of
the increase.
Not all countries provided data for all years, but this situation has been controlled in
the analysis.
Sources: Reitox national reports 2000, taken from national mortality registries or special
registries (forensic or police). See also standard epidemiological tables in EMCDDA
web site.
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half of those recorded in the United States (270 million
inhabitants). In recent years, the number of cases in the
EU has fluctuated between 7 000 and 8 000, whereas
the United States appears to present an upward trend
from about 13 000 to almost 16 000 in the same period
(ONDCP, the national drug control strategy, 2001
annual report).
Mortality among drug users
Problem drug users represent a very small proportion
of the population, but they concentrate dispropor-
tional health problems and, in particular, suffer very
high mortality.
Follow-up studies that consist of tracking groups of
problem users (usually opiate users recruited from
treatment centres) over several years have shown
consistently that opiate users have an overall mortality
rate (for all causes) of up to 20 times higher than
that of the general population of the same age. This
is due not only to drug overdose but also to
accidents, suicides, AIDS and other infectious
diseases. Further risk factors have been identified: the
mortality of injectors is two to four times higher than
that of non-injectors, while that of users infected by
HIV is two to six times higher than of non-infected
users. Combined use of opiates with other depressant
substances such as alcohol or benzodiazepines may
increase the risk of overdoses.
The mortality of problem drug users that do not use
opiates or do not inject their drugs is visibly lower,
although their health risks are more difficult to assess
with precision. In general, traditional drug treatment
centres record relatively few and selected cases of
heavy cocaine or amphetamine users and a substantial
proportion of them seem to be former or concomitant
opiate users, former injectors, or socially excluded
people. Different methodologies and/or sources may be
needed for these drug users other than for traditional
opiate users.
A multi-site study coordinated by the EMCDDA has
established cohorts in nine European sites (cities or
countries) following as far as possible a common protocol
developed as part of the key indicator ‘drug-related
deaths and mortality among drug users’. The study shows
substantial differences in overall mortality and causes of
death between locations.
Trends in mortality among drug users
The EMCDDA study mentioned above reveals that in
several locations mortality rates reached their highest
levels in the early or mid-1990s, decreasing in more
increases are probably related to a later expansion
of heroin use in these countries during the 1990s,
which may be explained by their sociological
evolution. Recording practices may also have
improved. The broad case definition used may
influence in part the marked increase observed
recently in Portugal.
• The United Kingdom presents a moderate but continu-
ously increasing trend. Other countries have a stable
trend, or trends are difficult to assess due to the recent
switch in the International Classification of Diseases
(9th edition to 10th edition), or changes in national
definitions.
Comparisons between estimates of drug-related deaths
for the EU and the United States should be made and
interpreted with extreme caution. Current European
definitions of drug-related death are heterogeneous and
the United States definition is somewhat broader and
includes psychoactive medicines. Even so, it is worth
noting that the number of cases recorded in the EU
countries (376 million inhabitants) amounts to roughly
Drug demand and drug supply
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NB: Comparability across study sites is still limited.
Sources: EMCDDA project CT.99.EP.07, coordinated by the Agency for Public Health, Rome. See also standard epidemiological tables on the EMCDDA web site.
Mortality from all causes in cohorts of opiate users recruited in treatment centres in several EU countries or cities
Standardised mortality rates (males and females)
Fig. 11
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(12) ‘Arrests’ for drug law offences are defined in different ways by the Member States. The term can, for example, refer to suspected
offenders or to charges for drug law offences. Please, consult the Statistical bulletin at www.emcdda.org for exact definitions.
Fig. 12 Drug most frequently involved in the ‘arrests’ for 
drug offences in the EU
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NB: n.a. = data not available.
(1) Central stimulants (of which amphetamines make up the larger part).
(2) All illicit drugs except hashish and marijuana.
(3) Among all drugs mentioned (alone or not) in Austria, Finland, Luxembourg, 
Sweden and UK; and among drug convictions in case of Sweden.
(4) Underestimated proportion since it represents offences for heroin only — it does
not include offences for ‘heroin’ and other drug(s).
(5) Among drug offences classifiable by drug (valid %).
(6) Germany: among all offences broken down by drug (for some offences, a break
down by drug is not available).
Sources: Reitox focal points, 2000.
recent years (Barcelona, Hamburg, Vienna and perhaps
Denmark — with information only in the last few years).
In Barcelona, this phenomenon has been particularly
evident: mortality reached over 50 per 1 000 users per
year from 1992 to 1996 before falling markedly, reflecting
mainly a drop in AIDS deaths and, to a lesser extent, in
overdose deaths.
Law-enforcement indicators
Offences against national drug legislation (such as use,
possession and trafficking) reflect differences in laws as
well as the resources and priorities of enforcement
forces. Variations in recording procedures and defini-
tions affect comparisons. However, wherever possible,
trends are compared.
‘Arrests (12) for drug law offences
Cannabis remains, in 1999, the most common drug
involved in ‘arrests’ — accounting for 45 % of the
drug-related arrests in Italy to 85 % in France. In
Sweden, amphetamines are slightly more frequent than
cannabis. In Portugal and Luxembourg, heroin is
predominant, while in the Netherlands most of the drug
offences are related to ‘hard drugs’ (drugs other than
cannabis and its derivatives).
The majority of the reported drug offences are
related to drug use or possession for use, except in
Italy, the Netherlands and Spain, where drug
offences concern only dealing or trafficking activities.
As in previous years, in 1999, Luxembourg reported
the majority of arrests involving offences for both
drug use and drug trafficking.
Trends
‘Arrests’ for drug law offences have been steadily increas-
ing since 1985 in the EU as a whole. Increases by over
sevenfold were reported in Finland, Greece and Portugal
while in Denmark, Italy, the Netherlands and Sweden,
increases were much lower (twofold or less).
2001 Annual report on the state of the drugs problem in the European Union
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In the last three years, the number of drug-related ‘arrests’
rose in most of the EU countries. The highest increases
were reported by Greece, Ireland, Portugal and Spain. In
1999, Belgium and the United Kingdom were the only
countries reporting a fall in the number of drug-related
‘arrests’ (13).
Drug users in prison
The prevalence of drug users amongst prisoners is princi-
pally estimated through a number of ad hoc studies
carried out at local level. Up to 90 % of prisoners report
a lifetime use of an illicit drug. Problem drug users and/or
intravenous drug users are less frequent but may represent
up to 50 % of the prison population in some areas (14).
Drug use within prison is reported in several countries.
Injecting drug users are less likely to inject inside prison
than in the community, but they are much more likely to
share injecting equipment inside prison.
Drug market indicators – 
seizures, price, purity
The data on drug seizures, price and purity analysed
below were provided by the Reitox focal points.
Differences with data published by Europol are due to
differences in reporting procedures (15).
Drug seizures are usually considered as indirect indicators
of supply and availability of drugs, although they also
reflect law-enforcement resources, priorities and strate-
gies, as well as the vulnerability of traffickers to enforce-
ment.Trends in quantities seized are biased since they may
fluctuate from one year to another due to a small number
NB: For definitions of ’arrests’, please refer to the complementary statistical tables at
www.emcdda.org.
Real values have been input for all countries in 1999 and for Belgium, Finland, the
Netherlands and Sweden in 1998 since data available do not allow the calculation of
moving averages in these cases.
The series is discontinued for Belgium in 1996 and 1997 (data not available).
Greece: 1998 figure relate to a number of charges.
Sources: Reitox national focal points.
’Arrests’ for drug offences in EU countries 1991–99: three
years' moving averages indexed (1991 = 100)
Fig. 13
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Access to drugs by 15 to 16-year-old students
From ESPAD school surveys, perceived access to drugs by
15 to16-year-olds seems to have increased between 1995
and 1999 in all participating EU countries (1) except
Ireland and the United Kingdom where it has been
decreasing. In 1999, cannabis was perceived to be ‘very
easy’ or ‘fairly easy’ to obtain by 20 to 60 % of the
students, heroin and cocaine by 5 to 20 %, and amphet-
amines and ecstasy by 6 to 38 %. Perceived availability
of illicit drugs is typically very low in Finland and quite
high in Ireland, Denmark and the United Kingdom.
(1) Participating EU countries: Denmark, Finland, France,
Greece, Ireland, Italy, Portugal, Sweden, United Kingdom.
Source: The 1999 ESPAD report. See page 9 for full reference.
of large seizures. The numbers of seizures are usually a
more useful indicator of trends at user’s level. This is
because in all countries they include a major proportion of
small seizures from the retail level of the market. Where
known, origin and destination of drugs seized may
indicate trafficking routes and producing areas. Price and
purity of drugs at retail level are reported by most of the
Member States, but data are scarce and do not allow for
accurate comparisons. However, they may give a rough
indication of the availability of different drugs, alongside
information on access to drugs at user’s level.
Heroin
In 1999, over seven tonnes of heroin were seized in the EU,
of which one third was accountable to the United Kingdom.
Heroin seized in the EU comes mainly from the Golden
Crescent (south-westAsia:Afghanistan, Pakistan), followed
by the Golden Triangle (south-east Asia: Myanmar, Laos,
Thailand), via Turkey, the Balkan Route and the Nether-
lands. However, increased trafficking via northeastern
European countries was reported, especially via Russia.
At street level, heroin prices varied between EUR 30 and
340 a gram in 1999 across the EU. The highest prices
are reported by Finland and Sweden. Heroin purity
ranges typically from under 20 to 35 %, but a higher
average purity is reported by Denmark, Finland and the
United Kingdom.
Trends
At EU level, heroin seizures increased up until 1991–92
and then stabilised. The number of heroin seizures has
grown steadily in Luxembourg, Portugal and Sweden
since 1985, while marked decreases were reported since
(13) Table 3 OL: Number of ‘arrests’ for drug law offences in EU countries (online version).
(14) Table 4 OL: Proportion of drug users among prisoners in EU countries (online version).
(15) Table 5 OL: Drug seizures in the EU countries, 1999 (online version).
Drug demand and drug supply
21
Fig. 14 Number of heroin seizures
in 1999
Quantities in kg are provided in brackets
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4 058
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NB: n.a. = data not available.
Differences that may be found between these data and those published by
Europol are due to differences in reporting dates.
Sources: Reitox national focal points, 2000.
(16) Figure 12 OL: Number of cocaine seizures in 1999 (online version).
(17) Figure 13 OL: Number of amphetamines seizures in 1999 (online version).
1996–97 in Austria, Belgium, Denmark, France, Germany
and Spain. In every Member State, the quantities seized
fluctuated over the period. In 1999, marked decreases in
the quantities of heroin seized were reported in Austria,
France, Greece, Ireland and the Netherlands, while in
Italy and Spain there were large increases in the amount
of heroin seized.
Heroin street prices are generally stable, although
Luxembourg, Portugal, Sweden and the United Kingdom
reported a recent decrease. Heroin purity is reported to
be stable or decreasing in all countries, except
Germany and the United Kingdom where it has been
recently increasing.
Cocaine (16)
Spain remains the country in the EU with the highest level
of cocaine seizures. The cocaine used in Europe comes
from Latin America (especially Colombia, Brazil and
Venezuela) via Central America, Spain and the Netherlands.
Retail price of cocaine varies from EUR 35 to 170 per
gram in 1999. The lowest prices are found in Belgium and
Spain and the highest in Finland. Cocaine purity is gener-
ally high, between 55 to 70 % in most of the countries,
except in Ireland which reported an average of 41 %
purity in 1999.
Trends
The total number of cocaine seizures rose steadily since
the mid – 1980s in the EU and seemed to stabilise in
1999. Cocaine seizures increased markedly in 1999 in
Luxembourg and Sweden, while they were decreasing in
Austria, Belgium and Denmark.
Following increases up until 1990, the quantities of
cocaine seized stabilised, and from 1994 on fluctuated
within an upward trend. In recent years, quantities went
up in France and Sweden and decreased in Greece,
Ireland and Luxembourg.
Cocaine prices are stable in most countries, but are
falling in Luxembourg, Portugal and United Kingdom.
Purity is generally stable, though increased in the United
Kingdom in 1999.
Synthetic drugs: amphetamines, 
ecstasy and LSD (17)
In Finland and Sweden, amphetamines are the second
most commonly seized drug. The United Kingdom
accounts for most of the amounts of amphetamines,
ecstasy and LSD seized in the EU.
There is a significant local production of synthetic drugs
in the Netherlands but production in other Member States
(Belgium and the United Kingdom) and in eastern
European countries (the Czech Republic, Estonia, Poland)
is also reported.
Amphetamines are reported to be sold at between EUR 5
and 60 per gram, while ecstasy tablets vary from EUR 5 to
25 each. Synthetic drugs are cheaper in Belgium and the
United Kingdom. Amphetamine purity is very variable,
from 3 % in Ireland to 55 % in Finland, but typically
ranges between 10 and 20 % in the EU. Tablets sold as
ecstasy contain — in 15 to 90 % of cases — ecstasy or
ecstasy-like substances (MDMA, MDEA, MDA).
Amphetamines (or metamphetamines) are found in 6 to
22 % of tablets, but various other psychoactive
substances may also be found.
Trends
Amphetamine seizures — both numbers and quantities
— have been on the rise since 1985. In 1999, the number
of amphetamine seizures continued to increase in
Finland and Sweden; while in other countries they were
stable or decreasing. Quantities peaked in 1997–98 in
most of the Member States.
NB: Some of the quantities seized are underestimated since data are not available.
Amphetamines data are not available for Austria since 1998. Since 1996, data for
Belgium include both amphetamines and ecstasy powder seized (tablets of
amphetamine and ecstasy seized are not included here).
Sources: Reitox national focal points.
Quantities of cannabis, cocaine, heroin and amphetamines
seized in EU countries  (1985–99)
Fig. 16
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NB: Data are not available for Greece; for some other countries, data are only available
since 1988 (Denmark, Portugal), 1993–96 (Finland) and 1997 (the Netherlands).
Numbers of seizures are underestimated in 1999 since data are missing for Italy and
the Netherlands.
Cannabis, heroin and cocaine data are not available in 1999 for Italy and the
Netherlands.
Amphetamines data are not available since 1998 for Austria and the Netherlands and
in 1999 for Italy. 1998 and 1999 data for Belgium include ecstasy seizures too.
Ecstasy — most of the data series start in the mid-1990s (except France, Italy, Spain,
UK). Data are not available in 1999 for the Netherlands and Italy. 1998 and 1999 data
for Belgium include amphetamines seizures too. Between 1985 and 1994, data for
Spain include LSD seizures too.
LSD data are not available in 1999 for Finland and the Netherlands.
Sources: Reitox national focal points.
Number of cannabis, heroin, cocaine, amphetamines,
ecstasy and LSD seizures in EU countries (1985–99)
Fig. 15
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(18) Figure 14 OL: Number of cannabis seizures in 1999 (online version). 
(19) Nederwiet: Dutch cannabis plants locally grown in the Netherlands.
number of cannabis seizures but on average they involve
smaller quantities (18).
Cannabis resin comes mainly from Morocco via Spain
and the Netherlands. The cannabis herb originates in
Afghanistan, Pakistan, and Lebanon, as well as in former
colonies. Local production is reported by most of the
Member States, especially nederwiet (19) production in
the Netherlands.
In 1999, the retail price of cannabis was reported to vary
between EUR 3 and 18 per gram of cannabis resin and
between EUR 3 and 12 per gram of cannabis leaves.
The percentage of the psychoactive substance in cannabis
resin — delta-9-tetrahydrocannabinol (THC) — ranges
from between 3 and 15 % on average, although samples
ranging from 0 to 70 % of THC have been reported in the
EU. THC content in cannabis leaves is generally lower,
around 2 to 7 %, with the exception of cannabis neder-
wiet which rates higher (8.6 % on average).
Trends
The number of cannabis seizures has risen steadily in
the EU since 1985. In 1999, they continued to rise in all
countries except Belgium, Denmark and the United
Kingdom where they decreased. Quantities increased
too but stabilised between 1995 and 1997. Since then,
most of the countries reported an upward trend, though
substantial decreases took place in Austria, Belgium,
Greece and the United Kingdom in 1999.
The price of cannabis is generally stable in the EU,
though has been falling in Portugal since 1997.
Ecstasy seizures increased up until 1996, then stabilised
and increased again in 1999 in all countries except
Belgium and Luxembourg. Amounts of ecstasy seized
followed the same upward trend since 1985, and then
stabilised from 1993 to peak in 1996 and fall in 1997.
They have been increasing again since then in all
Member States except Austria and Ireland. The highest
increases were reported in Finland, Germany, Greece,
Portugal, Sweden and the United Kingdom.
LSD seizures are less common. Both numbers and
quantities went up until 1993 and fell since then. In
1999, quantities continued to decrease in all
countries except Austria, Greece, Portugal and the
United Kingdom.
After significant decreases in the 1990s, amphetamine
and ecstasy prices have stabilised in the EU. However,
decreases were reported in 1999 for ecstasy in Portugal
and for amphetamines in Sweden, while in Greece, the
price of ecstasy tablets doubled. In recent years, the
proportion of tablets containing ecstasy or ecstasy-like
substances has increased in many countries while those
containing amphetamines (and metamphetamines)
decreased.
Cannabis
Cannabis is the most seized drug in every Member State
except Portugal where heroin seizures predominate.
Since 1996, Spain has been seizing the largest quantities
of cannabis. The United Kingdom reports a higher
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Responses to
drug use
This chapter presents an overview of developments in national and EU drug policies and
strategies. Responses to the drugs problem in the fields of education, health, social care
and criminal justice are also covered.
Political and strategic responses
At European Union level
The EU action plan on drugs (2000–04)
In June 2000, the European Council of Santa Maria da
Feira endorsed the EU action plan on drugs as a concrete
follow-up to the EU drugs strategy (2000–04). The strategy
set 11 general aims and six main targets for the EU and
the action plan lists around 100 specific activities to be
implemented by the EU by the end of 2004. The six main
targets are:
• to reduce significantly over five years the prevalence
of drug use, as well as new recruitment to it, particu-
larly among young users under 18 years of age;
• to reduce substantially over five years the incidence of
drug-related health damage (HIV, hepatitis, TBC, etc.)
and the number of drug-related deaths;
• to increase substantially the number of successfully
treated addicts;
• to reduce substantially over five years the availability
of illicit drugs;
• to reduce substantially over five years the number of
drug-related crimes;
• and to reduce substantially over five years money
laundering and the illicit trafficking of precursors.
Although not a legally binding document, the action
plan is another step forward in the fight against drugs
in the EU as it demonstrates the commitment of
Member States towards implementing the goals set out
in the strategy in 1999. The action plan contains
guidelines and frameworks for the actions and stresses
the importance of its regular evaluation — to be
undertaken in 2002 and, on completion, at the end of
2004.
The action plan pays particular attention to coordination
and information and it reflects the need for a balanced
approach where drug demand reduction and supply
reduction mutually reinforce one another. It also stresses
the importance of integrating the candidate countries
showing the EU’s commitment to assisting these
countries in dealing with the drugs problem as effec-
tively as possible.
At national level — drug strategies in the
European Union Member States
Heightened activity is reported in the Member States in
the area of drug policy review and revision. The status,
scope and content of these initiatives vary, but illustrate a
visible trend towards strengthening and improving drug
policy. This appears to be based on the mutual recogni-
tion that no single response is effective in tackling the
multifaceted drugs problem — and that multifaceted
responses are valuable when they form part of a coordi-
nated, long-term strategy.
Scientific assessment and regular evaluation are
recognised as essential in the review and revision of
drug strategies. An approach used in several Member
States is illustrated in Figure 17 which shows how
renewed political awareness of the drug problem
feeds into a cyclical process of scientific assessment,
evaluation, political debate and formulation, adoption
and action.
2C h a p t e r
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Drug coordination arrangements
The EU action plan on drugs (2000–04) encourages
Member States to establish and strengthen national
coordination mechanisms and/or to appoint a national
drugs coordinator with the objective of tackling drugs
with a global, multidisciplinary, integrated and balanced
strategy. It also calls on the Council to provide regular
opportunities for those responsible for drugs at a national
level to meet and exchange information on national
developments and increase cooperation (20).
Drug coordination bodies or functions exist in all
Member States, although major differences exist in their
structure and organisation. To provide a clear picture of
the drug coordination system in Europe, the EMCDDA
undertook a preliminary review in 2000 which will be
finalised in 2002. The results of this research (available at
http://www.emcdda.org) show a move in some Member
States to establish or strengthen coordination bodies at
central level. Some Member States (such as France,
Portugal and Spain) link all aspects related to drugs and
drug addiction in a body with highly hierarchical
decision-making powers and at the direct service of the
Prime Minister (Figure 19).
In other EU countries (such as Germany, Finland, Greece,
Italy and the United Kingdom) coordination takes place at
Fig. 17
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Fig. 18
Adopted 1998–1999
Austria The Vienna drug policy programme, 1999; Salzburg, action plan
France French drug strategy, 1999–2001 
Northern Ireland Drug strategy: drug misuse in Northern Ireland: a policy
statement, 1999
Norway Action plan for drug use reduction, 1998–2000
Portugal Portuguese drug strategy, 2000
Scotland Drugstrategy: tacklingdrugsinScotland:actioninpartnership,1999
Spain Spanish drug strategy, 2000–08
United Kingdom Drug strategy: ‘Tackling drugs to build a better Britain’, 1998–2008
Adopted 2000–2001
Austria Action plans: Lower Austria, Styria
Belgium Political note, 2001
Ireland Building on experience, Ireland’s National Drug Strategy, 2001–08
Luxembourg Action plan, 2000–04
Portugal Action plan, 2000–04
Scotland Scottish executive action plan ‘Protecting our future’, 2001
Wales TacklingsubstancemisuseinWales:apartnershipapproach,2001
United Kingdom National plan 2000/2001
Underway 2000–2001
Finland Review of the decision-in-principle for 2001–03
Greece All-parties parliamentary study on drug policy measures, 2000
Sweden A plan of action regarding drugs is to be released in 2001
(20) Article 1.1.3 of the EU action plan on drugs 2000–04, Cordrogue 32 9283/00.
Fig. 19
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an inter-ministerial level — without recourse to a central
coordination body — through regular contact and
meetings between the governmental administrations
involved in each of the several facets of the drugs
problem. Usually, in this second model, the responsibility
for drug coordination lies within the ministry/department
of social affairs or health. A drug coordinator might also
be present — responsible for matters relating to health
and social aspects but also in charge of liasing with the
governmental department working in other drugs-related
fields (Figure 20).
Legislation and prosecution
The EMCDDA is committed to monitoring main trends
and changes in drug laws. To this end, a drugs legal
database presenting EU drug laws, legal profiles and
comparative studies is accessible online at http://eldd.
emcdda.org.
Main developments recorded recently include that in
Portugal no penal sanctions will be applied to repress the
private use of illicit substances after 1 July 2001 (law
30/2000 adopted in November 2000). The drug-use
offender will instead be oriented to treatment or
counselling by specific commissions. Since May 2001,
cannabis use and possession in Luxembourg is punished
only with monetary fines (according to the law of 27 April
2001). The Belgian Government intends to issue a decree
in order to consider not punishable the ‘non-problematic’
use of cannabis.
Several reports indicate that individual drug use or
possession of illegal drugs for personal consumption are
not amongst the top priorities of European law-
enforcement authorities: more serious crimes and drug
trafficking are the main objects of judicial practice against
drug-related offenders. The new measures towards the
decriminalisation or non-prosecution of drug-use
offences implemented in some Member States seem to
confirm this tendency. A recent study on the prosecution
of drug-related offences, commissioned by the EMCDDA
in 2000, also found that the judicial process involving
possession/use of small amounts of drugs in private is
usually dropped before court stage. Public
possession/use, sale by drug users and acquisitive crimes
linked to drug addiction, however, often result in stronger
measures by prosecutors and courts.
A drug court programme opened in Dublin in January
2001 with the objective of rehabilitating drug abuse
offenders and tackling drug-related crime. This court —
similar to the Canadian, Australian and American drug
court models — is led by a judge specialised in drug
issues who deals exclusively with non-violent drug-
abuse offenders offering supervised treatment and
rehabilitation instead of prison. The Scottish executive
has also chosen to implement a drug court by the end of
2001, while in England a number of similar initiatives
are being piloted.
A revision of the federal law in Austria entered into force
on 8 April 2001 diminishing from 5 to 3 grams the thresh-
old limit considered as a large ‘quantity’. This will have a
repercussion on the distinction between misdemeanours
(acquisition and possession of small quantities) and
felonies (production and possession of large quantities).
Discussions have also taken place on the legal status of
medical cannabis.
Fig. 20
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In Germany, an amendment to the federal German
narcotic law defined a basic framework in which each
Land is able to define the minimum standards required
for the establishment of users’ rooms (that is, rooms
where injecting drug users can use drugs under hygienic
conditions). In this way the Land can decide whether to
allow consumption rooms. The law also establishes a
central register for substitution treatment and requires
training for physicians offering such treatment. In
Portugal, following public debate, a decree law is envis-
aged to regulate the setting up of users’ rooms. In
Luxembourg, the law 27 of April 2001 provides the legal
basis for the creation of users’ rooms.
As far as confiscation of criminal assets deriving from
drugs crimes is concerned, a draft bill has been
proposed in the United Kingdom to establish a Criminal
Assets Recovery Agency and to introduce a civil recov-
ery scheme to deprive criminals of illegal assets.
Similarly, the government in Finland submitted a
proposal to the parliament to confiscate proceeds of
drug-related crime in cases where illegal provenance is
suspected, the so-called reversal of burden of proof. In
Ireland, since 1996 when the Criminal Assets Bureau
(CAB) was established on a statutory footing (21), the
onus has been on the criminal to prove assets were
obtained legitimately. In Spain, for five years the national
plan on drugs has been administering confiscated illegal
profits. In 2000 alone, more than EUR 4.5 million,
derived from illegal, seized assets (boats, cars, money)
were ‘returned’ to fight against drugs: EUR 1 543 137 to
the repression of drug trafficking and EUR 2 978 014 to
drug prevention and rehabilitation programmes.
Drugs expenditure
In the context of monitoring responses in the Member
States to the drugs problem, comprehensive research
was carried out in 2000 to collect, analyse and
estimate the level of public expenditure on drugs. A
government’s expenditure, both in the area of health
care and law enforcement, was calculated through
measuring direct costs (expenditure directly labelled as
drug related) and indirect costs (expenditure incurred as
a consequence of the drugs problem in generic admin-
istrations, such as prisons).
Despite a number of differences, a similar policy of
allocation of resources in the drugs field can be seen
across the EU Member States. Globally, between 70 and
75 % of the budget is spent on law enforcement and the
rest on health care. 
Specific responses
Demand reduction
A range of interventions with different objectives and
operating in different settings are covered in this section.
An overview of the various settings and approaches in
demand reduction are provided in Figure 21.
Prevention measures
Prevention in schools
Drug prevention in schools remains a priority in all
Member States. Many teaching guidelines exist on
prevention and it may be necessary to carry out a
market overview in order to select the most appropri-
ate material (as has been done in Germany). In most
curricula, drug prevention is included in a context of
general health promotion. Peer-to-peer approaches
(that is students educating one another) are consid-
ered advantageous, although they are difficult to
establish and sustain. Parents´ involvement is consid-
ered crucial.
(21) Criminal Assets Bureau Act, 1996; Proceeds of Crime Act, 1999.
Classification of concepts in demand reduction
Fig. 21
Objective
Setting Prevention Treatment Harm reduction
Treatment in prisons (1) Harm reduction in prisons (1)
Coercive Alternatives to prisons
(‘You  have to stay with us’) Coercive care
Fixed settings Schools (1) Inpatient treatment
(‘You are here with us’)
Fixed premises Youth centres Outpatient treatment Low threshold services (1)
(‘Come to us’) GP treatment
Mobile 
(‘We look for you’) Outreach and Community work (1) Outreach work (1)
Media Internet, mass media (1) Telephone help lines
(‘You stay anonymous’) Early health responses (1) Early health responses (1)
(1) Indicates that the concepts are covered in this report.
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Increasingly, the police take an interest in primary drug
prevention in schools (in Belgium, France, the
Netherlands, Austria and Sweden) although there has
been some debate as to whether they are equipped with
the necessary educational skills for this type of work.
Students do take drugs (see Chapter 1, Drug use in the
school population) and are in the risk zone. This was
formerly largely denied since schools feared damage to
their image. Increasingly — in Spain, France,
Luxembourg, the Netherlands, Austria and the United
Kingdom — strategies are set up to develop school
policies on the prevention of risk behaviour, early inter-
vention and the facilitation of referral to addiction care.
Of particular concern are young people who drop out of
school or who are expelled. Spain reports standardised
interventions for this group and in the United Kingdom
95 % of secondary schools have policies covering drug-
related incidents.
Prevention in local settings and communities
Prevention activities in local communities have expanded
in the past years and take varying shapes and forms. All
Member States report different types of parents’ training
in the community. For example, in Spain, 25 000 families
participated in escuelas de padres in 1999, and, in
France, there are 75 special counselling centres for young
people to provide help for emotional, family or social
problems. In the Nordic countries, groups of parents walk
the streets of their community in order to provide support
to young people on weekend nights. In Denmark, 1 300
parents are involved in this activity.
Sports and athletic associations are given a more promi-
nent role in drug prevention than reported in previous
years in many countries including Belgium, Germany,
Greece, Spain, France, Italy and the United Kingdom. In
Germany, cooperation between sports clubs and drug
prevention has existed since 1994 and, in 2000, another
2 500 youth sports leaders were trained. A conference on
addiction prevention in sports clubs focusing on the
quality of drug prevention in sports clubs and on drug use
and sports clubs’ rituals and culture was organised in
Potsdam, Germany, in March 2000.
Coordination between actors is crucial for success. In
Denmark, Greece, Finland, France, Ireland, Italy,
Portugal, Sweden and the United Kingdom agreements
within local or regional authorities on drug prevention
strategies are in place or under development countrywide.
Treatment
Drug-free treatment
Currently little is known about the availability of drug-free
treatment across the EU. However, drug-free treatment
seems to be dominating the treatment offered in Finland,
Greece, Norway and Sweden. The tendency in those
countries is to have shorter treatment periods of three to
six months instead of one to two years, although in
Greece the mean duration of treatment is 12 months. A
recent meta-analysis carried out in Germany and cover-
ing several European countries concludes that there is a
positive relationship between the length of treatment and
treatment success. However, evaluation of different treat-
ment options is still to be improved.
Case management (low-threshold, intensive, person-
alised assistance) is increasingly set up to guide a drug
user through the treatment networks, for example in
Belgium, Germany and the Netherlands. The results of
five Dutch studies on dual diagnosis (the coincidence of
drug and psychiatric problems) show that case manage-
ment has slightly positive effects on patients´ satisfac-
tion, drug use, psychiatric symptoms, social skills and
utilisation of care services.
Mobilising pupils in prevention activities
At the request of the Ministry of Education in France, an
evaluation was carried out of the schools that took part in
a pilot programme ‘Les élèves acteurs de prevention’. The
pupils received guidance in organising campaigns and
transmitting knowledge on the issues concerned to their
fellow students. Their involvement in managing the
programme earned them the recognition of their peers.
The experiment proved a success for half of the schools
involved but even where it was not, it attracted a great
deal of interest from pupils in all schools. Its impact on
the atmosphere and quality of life in schools was very
positive, both in terms of the pupils’ perception and the
schools’ external reputation.
Evaluating types of treatment
In Norway, a project is evaluating types of treatment for
drug users to find out if some treatments obtain better
results than others and to find out which clients benefit
from which type of treatment. As drug users often use
several different treatments, the point of departure is that
each treatment builds on the achievements of any previ-
ous treatment — the hypothesis being that resources
invested are not lost.
2001 Annual report on the state of the drugs problem in the European Union
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The Netherlands provides a somewhat negative picture
of a difficult target group who fail to change their drug
using behaviour even after several attempts. The purpose
of inpatient motivation centres is to offer the opportunity
to drug users to recuperate, to help them develop their
social skills and to structure daily life in order to
increase their motivation to enter into regular care.
However, the drop-out rate at these centres is 60 % and
it is concluded that drug users who are not motivated
cannot be helped successfully.
Substitution treatment
Substitution treatment has been expanding moderately
in the EU over the last years. Greece, Finland, Norway
and Sweden have recently facilitated access to substitu-
tion treatment, mainly methadone. Buprenorphine,
which is the main substitution substance in France, has
been introduced in Belgium, Denmark, Finland (for
detoxification), Germany, Italy, Luxembourg, Norway,
Portugal, Austria and the United Kingdom, whereas
LAAM is prescribed in Denmark, Spain, and Portugal.
Studies are in progress in the Netherlands concerning
rapid detoxification with naltrexone as a medical treat-
ment, and this may be considered as an alternative to
other treatments. Naltrexone has been used in Portugal
for the last 10 years.
Heroin continues to be prescribed on a selective basis
in the United Kingdom. Experimental heroin prescrip-
tion for treatment of refractory chronic drug users is
available in the Netherlands within the context of
scientific experiment and a heroin prescription trial will
be initiated in Germany in 2001. Luxembourg is also
considering a heroin trial in 2002. Experts agree that
heroin prescription should only be considered when all
other treatment options available are exhausted. Heroin
prescription puts a heavy burden on clients and the
need to present themselves at the treatment centre two
or three times a day is disruptive to them. However,
there is evidence of its effectiveness for very deprived
drug users in terms of crime reduction, health improve-
ment and social integration.
Harm-reduction measures
Outreach work
Mapping outreach work (that is contacting drug users in
their own setting) in the EU is not an easy endeavour
since many activities are carried out locally by non-
governmental organisations and by structures that tend to
be quite complex. 
The origins of outreach work lie in traditional youth work
(with the aim of guiding drug users into treatment) and in
public health concerns (especially the prevention of
infectious diseases). Outreach work may include social
work among addicts, needle exchange, low-threshold
services and/or special services for ethnic minorities,
prostitutes and other hard-to-reach groups and is avail-
Substitution treatment among problem drug users
Table 1
NB: n.a. = data not available.
(1) For more details on national prevalence and problem drug use see section on problem drug use in Chapter 1 and online table 1 OL at www.emcdda.org. 
(2) Estimated proportion of problem drug users in substitution treatment.
(3) Prevalence figure only covers injecting drug users which may result in an overestimated substitution coverage rate.
(4) Information collected directly from national focal point.
(5) A substitution coverage rate of 100 % seems implausible, which suggests that the prevalence estimate of 4 694 (1 195) may underestimate current prevalence.
(6) Opiate users only.
Estimated prevalence of problem drug use(1) Estimated number of clients in substitution treatment Substitution coverage rate (%)(2)
Belgium 20 200 7 000 (1996) 35 (3)
Denmark 12 752–15 248 4 398 (4 298 methadone and 100 buprenorphine)(1 January 1999) (4) 27–34 
Germany 80 000–152 000 50 000 (2001) (4) 33–63 
Greece n.a. 966 (1 January 2000) (4)
Spain 83 972–177 756 72 236 receiving methadone (1999) 41–86 
France 142 000–176 000 71 260 (62 900 receiving buprenorphine and 8 360  receiving methadone) 40–50
(December 1999) (4)
Ireland 4 694–14 804 5 032 (31 December 2000) (4) 34–100 (5)
Italy 277 000–303 000 80 459  (1999) (4) 27–29 
Luxembourg 1 900–2 220 864 (164 in the official programme and +/– 700 prescribed mephenon 38–45
[methadone in pill form] by GPs; 2000) (4)
Netherlands 25 000–29 000 11 676 (1997) 40–47 
Norway 9 000–13 000 1100 (2001) 8–12 
Austria 15 984–18 731 4 232 (1 January 2000) (4) 23–26 
Portugal 18 450–86 800 6 040 (1 January 2000) 7–33
Finland 1 800–2 700 (6) 240 (170 buprenorphine  and 70 methadone) 9–13 
Sweden 1 700–3 350 (6) 621 (31 May 2000) (4) 19–37 
United Kingdom 88 900–341 423 19 630 6–22 
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able to problem drug users who are not in regular treat-
ment services in all Member States. Peer support among
drug users has been organised in Denmark, France, the
Netherlands, Austria, and the United Kingdom in order to
respond to the needs of drug users.
Outreach work is expanding in most Member States.
However, in Sweden, outreach work was more common
some 10 to 15 years ago and a new study reports that,
owing to a reduction in resources, many drug users are
not approached by any such services. New develop-
ments include outreach work for North-African drug
users in the Netherlands, and the introduction of special
services for women drug users in Denmark, Norway,
Austria and Sweden.
One specific outreach activity, which has been adopted
in France, the Netherlands, Austria and Spain is on-site
pill testing at dance events. Pill testing attracts visitors
because the content of pills is always of major concern to
them. Most projects also offer information talks, harm
reduction messages and crisis intervention. A recent
EMCDDA study (‘An inventory of on-site pill testing inter-
ventions in the EU’, EMCDDA 2001) suggests that pill
testing can efficiently warn against the unexpected and
dangerous effects of dance drugs.
Low-threshold services
Low-threshold services are expanding in most Member
States. Users´ rooms — that is rooms where injecting
drug users can use drugs under hygienic and safe
conditions — were legalised in Germany in February
2000, and one users’ room was introduced as a pilot
project in Madrid, Spain in 2000. In the Netherlands,
they have existed for several years where they also
serve heroin smokers and cocaine and crack users.
Similar initiatives are being discussed in Austria,
Luxembourg and Portugal. In relation to a discussion in
Denmark concerning the introduction of injection
rooms in association with existing low-threshold
services, the Danish Ministry of Health has chosen to
shelve this initiative as a result of international conven-
tions dealing with this matter.
Early health responses to new synthetic drugs
These measures aim to avert potential health problems
relating to the consumption of substances, unidentifiable
to the users, who themselves are not seeking contact with
treatment and counselling services i.e. unknown
substances consumed by unknown users. These responses
are implemented either through structural measures such
as the organisation of safe raves (staff training, provision
of water and chill-out facilities) or information measures
on party drugs through media campaigns, interactive web
sites and CD-ROMS, or by specifically providing informa-
tion on the results of on-site or off-site pill testing through
the Internet or special journals. Thus, these interventions
are sometimes linked to outreach work measures such as
on-site pill testing.
In Denmark, Spain, Ireland, Italy and the Netherlands
local authorities approach young people’s leisure venues
(such as clubs, bars and discos) to provide the staff with
training and support to enable them to respond more
effectively to drug-related situations.
The concept of ‘real time’ monitoring of youth scenes is
reported by Luxembourg. Following an initial evaluation
phase, the game kit ‘Ecstasia’ has been applied to differ-
ent youth settings and integrated in appropriate school
courses. It boosts discussion, sharing experiences and
finding alternatives to drug use, especially as regards
synthetic drugs. The group dynamics stimulated by the
Outreach project for homeless women
In Sweden, the Stockholm Social Services started an
outreach project in 2000 targeting homeless women,
many of whom have little or no contact with social
services. One of the aims is to motivate the women to
increase their contacts by providing them initially with
simple medical help. The project is exemplary in that it is
a joint venture between the social services, voluntary
organisations and the medical treatment sector.
Training for nightclub staff
In Ireland, training and support is given to nightclub staff
in order to enable them to respond more effectively to
drug-related situations in nightclubs. The first two phases
of the project involve the organisation of training
programmes for club owners/managers and door supervi-
sors. They focus on increasing their knowledge about
drugs, exploring their attitudes towards drugs and
examining legal, health and safety issues. The third phase
is designed to disseminate accurate information on drugs
to young club goers through distributing a credit card-
sized booklet known as the vital information pack (VIP) in
a number of venues including third level colleges and
clubs. In phase four, a one-day conference will be organ-
ised to gain support from the music/dance industry for the
development of acceptable policies in dance venues. The
final phase involves standardising training for door super-
visors and providing these elements in a modular form.
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game enable issues to be addressed to which young
people should be sensitised. The evaluation suggests
increasing the creative and action-oriented elements of
the game.
The Internet provides an enormous variety of drug infor-
mation reflecting all positions on drug policy, although
quality control of such information is not possible. Most
national prevention organisations as well as NGOs have
or plan their own homepage, mainly with information but
also with interactive features, for example the Italian Io
non calo la mia vita (http://www.iononcalo.it), the
Swedish Drugsmart (http://www.drugsmart.com) and the
drug search facility (http://www.drugscope.org) provided
by DrugScope in the United Kingdom. An innovative
initiative is reported from Finland where an anonymous
consultancy and self-assessment test is available on the
Internet (http://www.a-klinikka.fi/plimenu1.htm). The
EMCDDA database EDDRA (http://www.emcdda.org)
gives references to over 250 evaluated projects in the
field of demand reduction and is continuously growing.
Reduction of drug-related crime
Prevention of drug-related crime
All Member States have programmes for diversion to
treatment under specific conditions, for example the
gravity of the offence or the age of the offender. This is
considered to decrease the rate of subsequent crime,
although evaluation information is rarely available.
Drug users continue to pose a major problem in the
criminal justice system with up to 50 % of prisoners with
drug-related problems. Given the high turnover rate in
prisons, it is estimated that 180 000 to 600 000 drug users
pass through the system annually in the EU. The preva-
lence of drug use varies depending on the type of prison.
It is more significant in large and in short-stay prisons,
more prevalent in women’s than in men’s prisons.
Table 2 provides a rough overview of assistance to drug
users in prisons in the EU — the EMCDDA report
‘Assistance to drug users in prisons’ provides full details.
The UK Government has introduced drug treatment and
testing order (DTTO) schemes whereby courts can make
an order requiring offenders to undergo treatment either
as an alternative to prison or as a sentence in its own
right. The roll out of DTTO is estimated to result in some
3 425 orders being made by 2001. This is to be compared
to some 120 000 persons convicted of drug offences in
1999. Drug prevention advisory services, in conjunction
with probation services, will provide on-the-ground
support for the national roll out of DTTO, disseminating
practice findings from the pilot programmes and assisting
local drug action teams in developing appropriate
commissioning arrangements.
Drug treatment and testing order schemes
in the United Kingdom
Assistance to drug users in prison in the EU
Table 2
Drug-free treatment in prisons Substitution treatment in prisons Reduction of drug-related harm in prisons
Belgium Yes, in experimental phase Gradual detoxification with methadone Some local HIV prevention actions
Denmark Cooperation with private treatment Yes, if on methadone treatment before prison Cleaning fluid provided, hepatitis B vaccination
institution
Germany Yes Yes Syringes exchanged in some prisons
Greece Self-help groups No Information in some prisons
Spain Yes Yes Yes
Finland Substance abuse courses, Yes, if on buprenorphine/methadone before prison Cleaning fluid provided, hepatitis B vaccination
drug-free wards
France No Yes (methadone or buprenorphine) Information to prisoners, chlorine distribution
Ireland Limited Detoxification with methadone, maintenance for No
HIV positive prisoners
Italy Yes Yes No
Luxembourg Yes Yes, if on methadone treatment before prison and No
treatment initiation before release
Netherlands Yes, compulsory treatment for Limited, reduction programmes for longer-term prisoners Yes
hard core drug users
Austria Yes Yes Yes
Portugal Yes Yes Information, training of guards, condoms and bleach 
distribution, hepatitis vaccination
Sweden Yes No No
United Kingdom Yes Methadone detoxification. Also available: sofaxidine, Disinfecting tablets in some prisons, counselling
dihydrocodeine and naltrexone and information
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‘Back to the future’ in Finland
In Finland, the programme ‘Back to the future’ (funded by
the Integra programme of the EU) has been involved in
projects with young drug addicts. The project results
reinforce the notion that people facing unemployment
and income problems after recovering from drug abuse
problems are in an extremely difficult situation. The
problems they encounter include inadequate housing,
reduced working capacity, lack of vocational training and
problems associated with work and maintaining a drug-
free lifestyle. Education was available to the project
participants but they found it hard to approach educa-
tional systems and work options and it was not easy for
them to find employers willing to enter into apprentice-
ship contracts. Although the State automatically guaran-
tees the study loan, the banks refused to provide personal
loans because almost 90 % of the clients were not credit
worthy. The project found that the actions available to
social and health services are inadequate to resolve
multiple welfare problems. Active measures are required
of the rehabilitation system which involve an individual
and tailor-made approach transcending administrative
boundaries and adequate financing.
Quality assurance in demand reduction
In Austria, quality assurance procedures are becoming
increasingly important in the field of drug demand reduc-
tion. Guidelines for quality work and minimum standards
for all fields of addiction activities as well as for the case
management of substitution clients have been drawn up.
Minimum standards, as quality prerequisites for drug and
alcohol counselling, have been defined and will be
implemented in a stage-by-stage plan. In Vienna, special
competence centres were established, which are respon-
sible for networking and ensuring the transfer of informa-
tion to fields of activity that do not explicitly deal with
drug issues (such as youth work and health care).
Social rehabilitation and reintegration
Education, training, housing and employment are key
areas in the rehabilitation of drug users after treatment,
after imprisonment or in long-term substitution mainte-
nance programmes. However, it appears that this area of
assistance is still rather undeveloped even though profes-
sionals often emphasise that aftercare and reintegration is
a very important aspect of drug treatment and that
improvements in this field would be needed.
Evaluation
Evaluation is the key to ensuring the quality of drug-
related responses, as is adequate planning, infrastruc-
ture, professionalism, supervision, training, research and
networking. Quality assurance procedures are increas-
ingly being introduced in the demand reduction area in
the EU. Quality assurance initiatives concerning preven-
tion are reported from Germany, Greece, Finland,
France, Italy, the Netherlands and Austria, and quality
assurance of care from Germany, Greece, Luxembourg,
the Netherlands, Norway, Austria, Portugal and the
United Kingdom.
Training is established for general practitioners and other
health care professionals in Belgium, Germany, Finland,
Ireland, Italy, Austria and the United Kingdom, whereas
other countries — Greece, France, Italy, Luxembourg,
the Netherlands and Sweden — state that even if some
training is available for prevention, health and criminal
justice professionals, there is still a need for courses of
high quality.
Supply reduction
The following information has been extracted from
Europol reports.
New techniques of prompt intervention and disruption at
various levels of a criminal investigation avoid long,
drawn out and resource-intensive inquiries. New EU
judicial and law-enforcement cooperation structures
should be fully exploited by Member States, so as to
increase the sharing of information, both within Member
States and at international level.
The level of organised crime in the EU is increasing.
Production and trafficking of drugs appear to remain the
prime activities of criminal networks. The continuing
diversification and evolution of drug routes challenge
law-enforcement efforts. Criminals continue to examine
the successes and failures in the trafficking of their illegal
commodities and change their operations accordingly, by
altering routes, devising new methods of concealment or
recruiting new couriers.
According to Europol (EU situation report on drug
production and drug trafficking 1999/2000) an encourag-
ing project against the diversion of chemical precursors
was ‘Operation purple’, aimed at preventing the diversion
of potassium permanganate — a chemical used in the
production of cocaine — and bringing together 23
nations, including seven Member States, that produce,
import, export, or transit the chemical, as well as the
International Narcotics Control Board, ICPO/Interpol and
the World Customs Organisation. The project aims at
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preventing chemical diversion, taking into account that
the availability of precursors plays a key role in the
production of drugs. Since the start of its operation, 248
shipments of the chemical have been tracked, involving 7
778 tonnes. As a direct result, 32 shipments of potassium
permanganate have been stopped or seized, totalling
almost 2 226 tonnes. This is supposed to represent 29 %
of all shipments monitored. A similar operation will be
conducted on acetic anhydride, a chemical used in the
processing of heroin.
Further to the political developments aimed at increasing
judicial and law-enforcement cooperation, Europol’s
competence will be broadened to money laundering in
general, regardless of the type of offence from which the
laundered proceeds originate.
Currently, Europol and experts from Member States and
the EMCDDA are developing a harmonised database on
drug seizures, with common definitions and parameters,
to be introduced in all Member States. This should lead to
a standardised collection of data EU-wide, which will
allow for a better comparison and analysis of the drug
situation in the various Member States.
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Selected
issues
This chapter highlights three specific issues relating to the drug problem in Europe:
cocaine and ‘base/crack’ cocaine, infectious diseases and synthetic drugs.
Cocaine and ‘base/crack’ cocaine
Concern has been growing in the EU about increasing
use of cocaine; however, actual trends in cocaine use
and their consequences across the EU are difficult to
verify. Firstly, national data, for example, from surveys
or treatment centres do not reflect changes in preva-
lence and problems that occur in geographic patches
within specific cities or changes which are concen-
trated in particular social milieus. Secondly, current
information about cocaine often lacks clear, scientific
definitions — for example, information systems rarely
distinguish cocaine ‘base/crack’ from cocaine
hydrochloride or between the different ‘base/crack’
preparations. These different forms of cocaine have
different market features, different patterns of use, and
contribute to different problems, all of which need to
be understood for effective policy-making and demand
reduction responses.
Prevalence, patterns, and problems
Prevalence
Neither general population surveys nor school surveys
reveal a general increase in levels of cocaine use in the
EU. Only in the United Kingdom has there been a
confirmed increase in lifetime prevalence of cocaine use
among young adults aged 16 to 29. The Italian national
focal point reports that a range of sources in Italy has
shown that cocaine use is in second place to cannabis
and higher than amphetamine or ecstasy use.
A 1999 European schools survey shows that experimental
use of cocaine (lifetime prevalence) amongst students
aged 15 to16 remains low and is much lower than for
cannabis. In all the Member States included in the survey,
cocaine was reported to be less available than ecstasy
although there was considerable variation between
countries. Cocaine is reported to be easily available by
the greatest percentages of 15 to 16-year-olds in Ireland
and the United Kingdom (21 % and 20 % respectively)
and by the lowest percentage in Finland (6 %). However,
in all the EU countries surveyed, availability of cocaine
was considerably less than to the same age group in the
United States (2). Disapproval of cocaine use is very high
and more or less equal in strength throughout all the
3C h a p t e r
What are cocaine and crack?
Cocaine is a stimulant drug extracted from leaves of the
Erythroxylon coca bush and was developed to treat a
wide variety of illnesses in the mid-19th century. The
chemical name of the processed drug is cocaine
hydrochloride and it is generally sold ‘on the street’ as a
crystalline powder, known by a range of street names,
such as ‘coke’, ‘snow’ and ‘Charlie’. It is generally taken
intranasally and less frequently dissolved in water and
injected.
Cocaine ‘base/crack’ is a street term for cocaine that has
been treated for use by smoking or inhaling vapours to
provide immediate and intense effects. There are at least
three methods of ‘base/crack’ manufacture (1). One
method results in a clean product — by adding hot water
and ammonia or sodium bicarbonate and discarding the
excess liquid layer containing diluents. Another method
results in lower cocaine concentration — by heating a
paste of cocaine and sodium bicarbonate in a microwave
with all diluents remaining in the final product.
Cocaine and ‘base/crack’ are usually distinguished on the
basis of physical appearance and purity and further
complicated because some cocaine ‘base/crack’ is physi-
cally similar to cocaine hydrochloride.
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participating countries and equals the levels of disap-
proval applied to heroin.
Patterns
Although nothing dramatic is occurring in the general
population at national level, there are more marked
levels of cocaine use in certain social settings. Past
research on cocaine users showed that firm boundaries
distinguish recreational users of cocaine powder
(hydrochloride) from problem ‘base/crack’ users, and
cocaine injectors. A wide range of recreational cocaine
powder consumption patterns is found among groups of
people who frequent nightclubs and dance settings and
who use powder cocaine for social and utilitarian
purposes. These recreational users are distinct from the
marginalised groups, such as homeless young people,
sex workers and problem heroin users who smoke
‘base/crack’, or inject cocaine mixed with heroin, in
geographic patches within specific cities. However, the
boundary between powder cocaine and ‘base/crack’
may be weakened by an emerging trend in cocaine
smoking in recreational and nightlife settings and in
recent changes in the market. Firstly, a new trend of
mixing cocaine ‘base/crack’ with tobacco in a ‘joint’ for
smoking has been reported in five Member States — the
Netherlands, France, Greece, the United Kingdom and
Italy. Secondly, forensic science services have reported
that some cocaine ‘base/crack’ is physically similar to
cocaine powder (hydrochloride), which makes it difficult
for police and inexperienced users to make any distinc-
tion (8). And thirdly, in the United Kingdom, there are
indications that cocaine ‘base/crack’ for smoking is
being reconstructed and commodified with new names
such as ‘rock’ and ‘stone’ and these serve to distinguish
ready-to-smoke cocaine from ‘base/crack’ and push its
image up-market and closer to powder cocaine (4).
Source: The 1999 ESPAD report. See note on page 9 for full reference.
Lifetime prevalence of cocaine and cannabis
among 15 to 16-year-old school students
Fig. 22
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Lifetime prevalence of cocaine in targeted users surveys compared with population surveys
Table 3
(1) Release  (1997), Release dance and drugs survey: an insight into the culture, London.
(2) S. Henderson (2000), ‘Protecting and promoting the health of club-goers in Liverpool: An information campaign evaluation and market research project’, 1999–2000.
Sources: National focal points and references as indicated below. 
Country Clubbers Young adults from general population
LTP (%) Sample size (Year) and source LTP (%) Sample size Year and age range
Austria 42 50 (1999) Austrian ravers – – –
Belgium 45 154 (1998) Rock Festival, French Community – – –
Denmark – – – 3.1 14 228 2000 16–34 
Finland – – – 1.2 2 568 1998 15–34 
France 56 896 (1999) Techno rave parties,  Médecins du monde 1.9 2 003 1999 15–34 
Germany
Former West – – – 2.2 6 380 1997 18–39
Former East – – – 0.4 1 620 1997 18–39 
Netherlands 48 456 (1998) Amsterdam clubbers,  Questionnaire (23% response) 3.7 22 000 1997/98 15–34 
Spain – – 4.8 12 488 1999 15–34 
United Kingdom 62 517 (1997) Release drugs and dance (1) 6.4 10 293 1998 16–34
18 
‘crack’
50 100 (1999) Clubbers in Liverpool (2)
Northern Ireland 45 106 (2000) Ecstasy users in Northern Ireland 
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Prevalence of cocaine use is much higher among subpop-
ulations with high prevalence of other drug taking than it
is among the general population of young adults. Table 3
(Lifetime prevalence of cocaine in targeted user settings)
illustrates a substantial difference between the relatively
high lifetime prevalence of cocaine taking amongst young
‘dance goers/clubbers’ and the much lower rates amongst
the more general population of young adults. The
relatively high costs of cocaine, combined with the short
duration of its effects, mitigate against regular recre-
ational use and a high level of disposable income may be
a significant factor in regular use. In recreational nightlife
settings, there is a tendency for some people to drink
significantly more alcohol than usual with cocaine.
Cocaine serves to increase sociability by moderating the
undesirable effects of alcohol.
Problems
Between 1994 and 1999 the number of clients seeking
treatment for problems associated with cocaine as their
main drug — as a proportion of the total clients seeking
treatment — increased substantially in Spain and the
Netherlands. Germany, Greece and Italy also show a
proportional increase in cocaine treatment and Ireland
showed an increase until 1998 (22). The United Kingdom
and the French and Flemish-speaking parts of Belgium
also reported an increase. There is a lack of comparable
research on cocaine users in treatment in the EU and the
proportional increases in clients seeking help for cocaine
problems may indicate a real increase in cocaine
problems but may also be the result of a reduction in the
number of clients seeking help for opiate problems or a
result of former opiate clients switching their main drug
problem to cocaine. The development of services that are
increasingly attractive to cocaine users may also influ-
ence treatment figures. Some drug treatment services
have reported that, among clients in treatment for heroin
dependence, there has been an increase in cocaine use,
particularly smoked as ‘base/crack’ or taken intravenously
with heroin. 
Figure 23 provides an example of the localised increase
in ‘base/crack’ users which are not reflected at national
level. In Frankfurt, the percentage of ‘crack’ users
amongst the total addicts registered by police increased
fourfold between 1996 and 1999.
Health service providers and cocaine users rarely report
fatalities, or negative physical health, as a direct conse-
quence of sniffing powder cocaine and because recre-
ational users tend to use cocaine alongside large
amounts of alcohol, or other drugs, it is difficult to
identify the causes of negative experiences. However,
Luxembourg, the Netherlands, and Italy report an
increase in the number of drug fatalities and Spain
reports an increase of hospital emergencies in which
cocaine was implicated in addition to other drugs.
Raised awareness among hospital emergency staff of the
potential role of cocaine in cardiovascular disturbances
could lead to higher rates of reporting (4).
Severe health, social and psychological problems associ-
ated with smoking cocaine ‘base/crack’ have been identi-
fied, particularly among marginalised groups, such as
problem opiate users, homeless and other disadvantaged
youth, and female sex workers. The extent to which
problems are direct consequences of the use of this form
of cocaine per se, or the frequency and amount of its use,
or of pre-existing social/psychological and drug
problems, is not clear.
Market
In 1999, the number of cocaine seizures increased
markedly in Luxembourg and Sweden whilst they
decreased in Austria, Belgium and Denmark. Retail level
prices of cocaine reported range from EUR 24 per gram to
EUR 170 with cities such as Amsterdam and Frankfurt at
the lower end and Member States such as Sweden and
Finland at the higher. In the United Kingdom and France,
retail prices have decreased but purity remained gener-
ally high between 55 and 70 % until late 1999 when, in
the United Kingdom, there was a sharp decline in the
mean purities of crack (10). Geographical variations in
price within Member States are marked. Small quantities
of cocaine, in parts of a gram or in the form of ‘balls’ or
‘rocks’, are available for less than EUR 15 in some cities,
particularly in those with open drug scenes and where the
cocaine concentrations may drop substantially (for
example, Frankfurt, Milan, Paris, London, Manchester
and Liverpool). Cocaine distribution takes place primarily
(22) Figure 15 OL: Cocaine: trends for new clients admitted to treatment (online version).
Source: PPF, Rauschgift und Kriminalität, several years in L. Paoli 2000.
Example of localised increase in percentage of cocaine
and crack users in Frankfurt
(total addicts registered by police 1996–99)
Fig. 23
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through chains of friends of friends but in some cities
open dealing takes place within recreational nightlife and
street settings. House dealing and delivery services have
been greatly facilitated by the increased convenience and
protection (in the form of anonymity) afforded to dealers
by mobile telephones (4, 5, 6, 7).
Increased availability of ready-to-smoke (‘base/crack’)
cocaine in a number of European cities (Amsterdam,
Rotterdam, London, Liverpool, Manchester, Frankfurt,
Milan and Paris) has been reported but methods for
preparing it (and the subsequent cocaine concentration
levels, which can rise to 100 %) vary and create
confusion for drug information systems, and the lack of
scientific definition for street terms such as ‘crack’ and
‘base’ pose problems for education and prevention
responses. At street level, cocaine may be sold already
mixed with heroin.
Spain, Belgium and the Netherlands are reported to be
major transit points for cocaine from Latin America
(Colombia, Brazil and Venezuela in particular) to the rest
of the EU. In 1999, six cocaine processing laboratories
were reported as having been dismantled in Spain and
subsequent increases in the wholesale price of cocaine in
Spain have been attributed to this.
Intervention projects and new approaches
The EU response to the increase in cocaine and crack
use has taken three main forms in the field of demand
reduction. During the 1990s, a small number of cities
developed specialised services to address the need of
primary cocaine problems and to target especially
vulnerable groups, such as Jugendberatung und
Jugendhilfe e.V. in Frankfurt and ‘Take five’ in
Rotterdam. Some Member States report efforts to adapt
existing structures to meet the needs of problem cocaine
and crack users. For example, in France and the United
Kingdom multidisciplinary strategies are being devel-
oped among involved professionals to collect and
exchange information about the needs of cocaine and
crack users in order to develop appropriate training and
adapt existing models and treatment services to provide
the type of services which will be more effective in
meeting the needs of cocaine and ‘crack’ users. Thirdly,
some Member States have placed emphasis on the need
to address the criminality and health consequences of
multiple drug use in general.
Data on responses to cocaine problems from the private
sector are difficult to obtain but, nevertheless, this sector
is likely to play a significant role in the treatment of more
socially privileged cocaine problem users.
Examples of treatment for cocaine problems
Few treatment responses have been described in the
reports from the Member States. However, Germany and
the Netherlands highlighted interventions specifically
designed for cocaine problems.
In Frankfurt, the youth organisation, Jugendberatung und
Jugendhilfe e.V. offers a treatment process targeted at
cocaine addiction, which is tailored to the needs of each
individual client. The initial ‘crash phase’, lasting a few
days, takes place either in an outpatient setting with
psychosocial support or as a detoxification process in a
hospital. The next phase involves six weeks of inpatient
treatment where the client follows a daily schedule,
including group and individual treatment sessions. The
recovery phase, either in an outpatient or inpatient
setting, aims at re-establishing or improving contacts and
relations with family, relatives or partners.
In Rotterdam, ‘Take five’, a treatment programme for
heavy ‘base/crack’ users has been running since 1996.
The programme, administered by municipal health
services, operates like a low-threshold service. In the first
phase, street workers contact ‘base/crack’ users at differ-
ent locations such as drug dealing spots, user rooms or
crisis centres. In the second phase, the patient frequents a
so-called ‘time out location’ which offers support 24
hours a day with a general practitioner and psychiatrists
available on request. The aim of the third phase is to
stabilise the health of the client and start rehabilitation.
The Rotterdam experiment reports that acupuncture is
very popular among their clients for relaxation.
Policy issues
In the EU there is a market of recreational drug
consumers with disposable incomes who are either wary
of the unreliable content of ‘ecstasy’ tablets and the
possibility of associated acute and long-term health
risks, or are jaded with their past experiences of MDMA
and its unpleasant early to mid-week after effects.
Research shows that, from the perspective of recre-
ational cocaine users, cocaine is considered more
predictable, versatile and unobtrusive than ecstasy and
the after effects of cocaine are considered less severe or
unpleasant and shorter-lived than the after effects of
ecstasy or amphetamines (3).
Research on cocaine users has identified clear social
distinctions and sharply separate subcultures between
users of cocaine powder (hydrochloride) and smokers of
‘base/crack’ — but the boundaries may be called into
question by the recent changes in the market and an
emerging trend of smoking cocaine ‘base/crack’ mixed
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with tobacco in ‘joints’ in recreational and nightlife
settings. The result of such changes may weaken the
taboos against ‘base/crack’ smoking, which have existed
and which have been providing informal controls to
prevent diffusion of crack into mainstream recreational
drug culture. These signs of erosion in informal social
controls over the use of ‘base/crack’ cocaine make early
response all the more urgent.
A positive utilitarian, and ‘up-market’ image of cocaine
powder and perhaps also of cocaine ‘base/crack’,
combined with the existence of affluent potential
consumers, could lead to a diffusion of cocaine use in the
EU, including ‘base/crack’. This potential for diffusion
should be treated with caution as biased news coverage
about ‘base/crack’ can lead to the construction of myths
about its use, which may divert attention from persistent
structural problems facing some inner city areas (9).
Sources
(National focal point reports, 2000)
1. The Forensic Science Service, Drug abuse trends, No 9,
Metropolitan Forensic Science Laboratory, London 1999.
2. The 1999 ESPAD report, see page 9 for full reference.
3. A. Boys et al., Cocaine trends: A qualitative study of young
people and cocaine use, National Addiction Centre, London,
2001. 
4. A. Ghuran and J. Nolan, ‘Recreational drug misuse: issues for
the cardiologist’, Heart, Vol. 83, 2000, pp. 627–633.
5. K. Brain, H. Parker and T. Bottomley, Evolving crack cocaine
careers: New users, quitters and long-term combination drug
users in NW England, University of Manchester, 1998.
6. L. Paoli, Pilot project to describe and analyse local drug
markets: First-year report to the EMCDDA, Max Planck Institute,
Freiburg, 2000.
7. P. Blanken, C. Barendregt, L. Zuidmulder, ‘Retail level drug
dealing in Rotterdam’ in Understanding and responding to drug
use: the role of qualitative research, EMCDDA Scientific
Monograph Series, No 4, 2000.
8. Drug abuse trends, Issue No 10, New Series, October/
December 1999.
9. D. Hartman and A. Golub, ‘The social construction of the
crack epidemic in the print media’ Journal of Psychoactive
Drugs, Vol. 31 (4) 1999.
10. Home Office Statistical bulletin, 2000.
Infectious diseases
Prevalence and trends
HIV
The prevalence of HIV infection differs much between
countries — and within countries, between regions and
cities. Although divergent sources and data-collection
methods make comparisons difficult, available data
indicate average levels of infection among different
subgroups of injecting drug users (IDUs) that roughly vary
from about 1 % in the United Kingdom to 32 % in Spain
(see Figure 8, Chapter 1).
HIV prevalence seems to have stabilised in most
countries since the mid-1990s after the sharp declines
that followed the first major epidemic among IDUs in the
1980s (see Figure 24). In some countries (Austria,
Luxembourg, Ireland, the Netherlands, Portugal and
Finland) transmission may again be increasing among
subgroups of IDUs (See box on page 16, Chapter 1).
Recent transmission may be clearer if one looks specifi-
cally at prevalence in IDUs aged less than 25. HIV infec-
tions in this group must have occurred on average more
recently, as most IDUs start injecting at between the ages
of 16 and 20 (1, 2). The trends in this age group, as far as
data are available, are more marked than general preva-
lence and sometimes even in the opposite direction. In
Finland, for instance, a large outbreak occurred in
1998–99, as can be seen from HIV notifications data
(Figure 25). After 1999, overall prevalence declined, as
indicated by data from needle exchanges (Figure 24);
however, prevalence in young IDUs increased from 0 %
in 1999 to about 4 % in 2000. This might indicate that
once new infections among older injectors began to
decline due to saturation (most persons at risk have
become infected) and/or behaviour change of those at
risk, new infections mainly took place among younger
injectors, who often have higher levels of risk behaviour.
Sources: National focal points. For primary sources see complementary statistical tables at
http://www.emcdda.org.
Trends in HIV prevalence in IDUs from
different sources, all ages and age under 25
Fig. 24
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In several countries, HIV prevalence is consistently higher
in female IDUs than in male IDUs. This may be due to
higher levels or different ways of needle sharing and/or
higher sexual risk of female IDUs.
AIDS
The countries that have been most affected with AIDS
among IDUs are mainly in the south-western part of the
EU, notably Portugal, Spain, France and Italy (23).
Incidence of AIDS varies greatly between countries, as
does HIV, but the general trend is downward (Figure 26).
This decline is probably the result of new treatments
among IDUs that delay the onset of AIDS. Therefore,
AIDS incidence is now considered as a less reliable
indicator of HIV transmission than before about 1996.
Spain, which had the highest yearly AIDS incidence
among drug users, has recently been surpassed by
Portugal, the only country not showing a decrease. This
may indicate limited uptake of HIV treatment (as shown
by a recent study) and/or increased HIV transmission
during the 1990s. However, the increase in Portugal
shows signs of levelling off during 2000.
Hepatitis C
Prevalence of hepatitis C infection is higher and more
similar across the EU than prevalence of HIV. Between
40 % and over 90 % of IDUs are infected with hepatitis
C virus (HCV), even in countries with low rates of HIV
infection such as Greece (see Figure 9, Chapter 1).
Chronic HCV infection incurs substantial health
problems, and in the long run (decades) may lead to
serious health consequences, including severe liver
damage and premature death. The proportion of chronic
infections that lead to severe health problems is still very
unclear, but there are recent indications that in IDUs it
may be lower (perhaps 5 to 10 %) than previously
thought (20 to 30 %) (3, 4). The extremely high levels of
HCV infection among IDUs in Europe may, however, still
lead to a large health burden due to liver disease among
(ex-) IDUs over the coming decades.
Trends in hepatitis C infection, for the few countries
which could provide these, show both important
decreases and increases in Austria, Portugal and Greece
depending on source (geographic location) and age
group (Figure 27). These may reflect different popula-
tions of IDUs with a different epidemiology of infections.
However, it is also possible that the trends reflect testing
policies that relate to the recent introduction of HCV
testing. For example, those with highest risk may partici-
pate first when a voluntary HCV test is offered such that
prevalence in subsequent years appears to decline. Only
following the trends over a longer period can confirm
the apparent trends. This potential bias may be less
important for HIV tests, which have been available for
many years.
Hepatitis B
Prevalence of antibodies against hepatitis B virus (HBV) is
also high, but seems less similar across the EU than preva-
lence of HCV. In the case of hepatitis B, the presence of
antibodies indicates whether one has ever been infected,
unlike for HCV and HIV, where a positive antibody test
mostly indicates current infection. However, antibodies
against HBV may also indicate vaccination. This means
that vaccination practices, which may differ much
between countries, need to be taken into account when
interpreting HBV antibody prevalence. The proportion
with no antibodies indicates IDUs who are still at risk of
infection and should receive vaccination. Vaccination of
IDUs is especially important as hepatitis B (also hepatitis
A or D) infection can be very dangerous and even deadly
if one is already infected with another hepatitis virus,
such as HCV. In the EU, roughly between 20 and 60 % of
NB: Data for Ireland are positive HIV tests in IDUs.
Sources: National focal points.
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IDUs have antibodies against hepatitis B. Self-reported
data from studies in some countries suggests that only
about 10 to 30 % of IDUs may have been fully vacci-
nated (5, 6, 7, 8). This suggests that a large potential
health gain through vaccination exists (24).
Easier to interpret than HBV antibodies is the prevalence
of HBsAg (the serological marker that indicates that the
hepatitis B virus is still present). This indicates current
hepatitis B infection, which can be either recent or
chronic infection. The level of HBsAg thus indicates the
potential for severe long-term complications and for
spread to others through injecting risk behaviour or
sexual transmission. Prevalence of HBsAg is only avail-
able from a limited number of countries, but appears to
differ much and is in some cases high (Figure 28). In
northern Greece, IDUs in methadone programmes may
have experienced an important outbreak of hepatitis B
infection prior to 1998, as levels were extremely high in
1998 but strongly declined between 1998 and 1999. In
Belgium, data from IDUs in treatment indicate a steady
increase in current HBV infection (HBsAg) between 1997
and 1999. In Portugal, recent data indicate a decline in
current HBV infection. In Norway, notification data
indicate a strong increase in HBV (and HAV) infections
among IDUs.
Other STDs, TB, endocarditis and Clostridium outbreak
Other infectious diseases that can be important among
IDUs are TB, which is not transmitted by injecting drug
use but is especially high among drug users in Spain and
Portugal, due to its strong association with HIV infection
and AIDS. Other sexually transmitted diseases (STDs),
such as syphilis and gonorrhoea, can also be high among
drug users, especially drug-using street prostitutes, if they
have no access to low-threshold medical services. This
may cause important transmission to non-drug users,
while these STDs also form an important risk factor for
HIV infection. Injecting drug users further often have high
prevalence of other infections which can be life threaten-
ing, such as abcesses on injecting sites or endocarditis
(infection of the heart valves), which can often easily be
treated if services are available.
Between April and August 2000, a very large outbreak of
Clostridium novyi infection occurred in Scotland,
Ireland, England and Wales, resulting in 104 cases of
severe illness and 43 deaths among young people. The
outbreak was probably related to contaminated heroin
in combination with specific modes of injection (intra-
muscular or subcutaneous rather than intravenous). It
showed, in a dramatic way, how large the potential is for
severe health problems among IDUs, which can be
much larger and more life-threatening than health
problems due to other and more prevalent patterns of
drug use.
Determinants and consequences
Injecting drug use
Among drug users, infections such as HIV and hepatitis B
and C are mainly transmitted through injecting drug use.
This is largely due to sharing of injecting materials such as
needles and syringes, and sharing of paraphernalia such
as cotton, water and spoons. It is probable that in situa-
tions of increasing injecting drug use populations of
injectors are especially vulnerable to rapid spread of HIV
and hepatitis.
The timing and magnitude of the AIDS epidemics in
different countries may have largely been determined by
timing and magnitudes of epidemics of injecting drug use.
Sources: National focal points. For primary sources see complementary statistical tables at
http://www.emcdda.org.
Trends in HCV prevalence in IDUs from
different sources, all ages and age under 25
Fig. 27
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Prevalence of current HBV infection
(HBsAg) in IDUs from different sources
Fig. 28
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These epidemics of injecting drug use probably occurred
earlier in northern European countries such as the
Netherlands (1970s and 1980s) but remained relatively
contained, while occurring later in southern European
countries such as Spain, Italy and Portugal (1980s and
1990s) and at higher rates. The occurrence of HIV
epidemics may have therefore depended on a delicate
balance between timing and magnitude of injecting drug
use epidemics, awareness of AIDS (not existing in early
years) and the timing and large-scale introduction of
preventive measures.
The importance of injecting among drug users (in Europe
mainly of heroin alone or together with other substances),
may further depend on preferences and cultural habits of
drug users or on the type of heroin available on the
market (water-soluble and injectable or not). Also price
and purity probably play a role, as injecting heroin is
more efficient and therefore cheaper than smoking it. Fear
of AIDS is thought to have much less influence on the
decision to inject or not.
At the moment, it is not known how to prevent inject-
ing drug use. Injecting drug use, or heroin use by any
route, may depend on a range of personal and societal
factors such as behavioural and/or family problems
and unemployment. Substitution treatment, however,
can be very effective in reducing injecting and inject-
ing risk behaviour among heroin users (9).
Injecting drug use has decreased strongly during the
1990s in most, but not all, countries. As a consequence,
rates of injecting drug use (measured among opiate users
entering treatment) differ strongly, from a low of about
10 % in the Netherlands to a high of about 70 % in
Greece. Recent trends in injecting are not available
except for Ireland, where they show a continuous
increase, consistent with a recent increase in the number
of IDU-related HIV positive tests.
Injecting risk behaviour
Among IDUs, spread of infections is mainly determined
by injecting risk behaviour, notably ‘needle sharing’
(giving or receiving a used needle from or to another
person). Transmission is also possible through the sharing
of injecting equipment such as water, cotton or spoons,
which are probably even more important in the case of
hepatitis B and C. Unhygienic injecting may even cause
transmission of hepatitis if no materials are shared, for
example via blood contamination of hands, tables or
other surfaces.
Other risk behaviours include front or backloading
(injecting heroin from one syringe into another in order to
measure even shares). Preliminary data on needle sharing
indicate that this is, in general, still very high among
IDUs, ranging from 10 to 17 % in the Netherlands
(recent borrowing of used needles), to 64 % in Ireland
(needle sharing in last four weeks) and 75 % in England
and Wales (sharing of needles and paraphernalia) (25).
Most of these data may still underestimate the amount of
risk behaviour through indirect sharing (front or
backloading), sharing of materials other than needles, etc.
On the other hand, needle sharing often occurs between
steady partners who both know they are not infected,
which may be relatively safe.
Sexual risk behaviour
Sexual transmission of HIV and HBV is much less
efficient than transmission through needle sharing, while
sexual transmission of HCV is thought to be very low.
However, when the level of infection (prevalence) is high
among IDUs, sexual transmission and transmission from
mother to child of HIV and HBV may become important.
IDUs may thus form so-called core groups or pockets of
infection for continued transmission to the wider popula-
tion. An efficient way of preventing sexual transmission is
the use of condoms. Condom use has greatly increased
among drug users since the 1980s, especially among sex
workers who usually report high rates of condom use
with their clients. However, condom use is usually low
with private partners who therefore remain a major risk
group for infection.
Consequences and costs
The consequences of an infection with HIV are severe.
HIV infection leads to AIDS on average after about 10
years, which by that time incurs great costs to the individ-
ual and to society due to chronic infections, hospitalisa-
tions and premature death.
Infection with hepatitis B in the majority of cases resolves
itself spontaneously, however, in an important proportion
of cases (2 to 8 % among adults, 10 to 15 % in adoles-
cents and much higher in children) it leads to chronic
infection, which in the long term can lead to severe liver
disease and premature death. As hepatitis B and HIV can
easily be transmitted sexually or from mother to child,
these infections among IDUs are an important threat to
the population at large.
Hepatitis C remains chronic in most cases (possibly 70 
to 80 %) and therefore IDUs are still a potential major
(25) Table 6 OL: Needle sharing among injecting drug users in some EU Member States (online version).
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source of infection. Hepatitis C infection, like hepatitis B,
has the potential of severe liver disease and premature
death in the long run (decades). The combination of
different hepatitis infections (including hepatitis A) at the
same time can be especially dangerous and often leads to
acute liver failure and death.
A preliminary estimate of future health care costs of one
year of drug-related infections of HIV, HBV and HCV in
the EU amounted to about 0.5 % of the total EU budget
for health care (Figure 29).
Harm-reduction responses
In most of the EU, the introduction of harm-reduction
measures — such as increased access to sterile needles
and syringes, greater availability of condoms, and HIV
counselling and testing — has helped to control HIV
transmission among injectors. Substitution treatment,
which can greatly reduce the frequency of injecting, is
also available in all Member States, mostly in the form of
oral methadone, but in most countries large improvement
is still possible in terms of coverage. (See Chapter 2,
demand reduction, treatment, substitution treatment).
While there is evidence that harm-reduction measures
have helped to reduce the prevalence of hepatitis C
among injectors, it has not controlled its spread (10).
The persistence of hepatitis C infection among young
injectors requires innovative approaches to harm
reduction. The introduction of medically supervised
injecting rooms and controlled heroin distribution are
two such approaches being considered by some EU
countries. However, both pose ethical and legal diffi-
culties and may necessitate a change in drug laws. In
those countries where injecting rooms have been
established (United States, Australia, Germany,
Switzerland and the Netherlands), their effectiveness
has yet to be assessed.
Important aspects for gauging the availability of harm-
reduction measures are provision of services and cover-
age of the IDU population. Based on estimates of
problem drug use and rates of IDU among opiate users in
treatment, preliminary estimates have been derived of the
size of the IDU population in EU countries. Using these
estimates a rough picture emerges of the provision of
syringe exchange programmes (SEPs) (distribution points)
per country (see Figure 30) and the number of needles
exchanged through syringe exchange programmes per
1 000 IDUs per year (26). Although country specific
estimates may not be reliable, overall it appears that
syringe exchange programmes in most countries for
which data are available are still not providing a sufficient
number of clean needles for IDUs, with the possible
exception of the United Kingdom (England and Wales)
and Spain.
(26) Figure 18 OL: Syringes distributed or exchanged through syringe exchange programmes per estimated IDU per year
(online version).
Source: M. J. Postma, L. G. Wiessing and J. C. Jager, ’Pharmaco-economics of drug addiction;
Estimating the costs of HCV, HBV and HIV infection among injecting drug users in EU-
countries’, Bull Narc. (in press).
Estimated future healthcare costs of one year of drug-related infections
for HCV, HBV and HIV, in millions of euro for 10 EU countries
(total for EU as a whole EUR 1.89 billion – 1995 price level)
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Provision of syringe exchange programmes
in some EU countries
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A French study estimated the average number of injec-
tions for a daily injector (in the previous month) to be
3.6 per day, implying more than 1 300 injections per
year per daily injector. (93 % of the sample of needle
exchange attenders were daily injectors.) (11) However,
this average may strongly depend on substances
injected (opiate users who also inject cocaine may
inject much more frequently) or income (IDUs with
little money may inject much less). Better and country
specific estimates of IDU population size and number
of injections are needed in order to assess the
coverage of syringe exchange programmes and thus
their potential for effective prevention of drug-related
infections (27) (28).
Sources
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Synthetic drugs
This section completes the data and analysis provided in
other sections of the annual report with a summary of the
main questions, concerns and challenges surrounding
synthetic drugs.
Spread of use
While the global picture in 2000 confirms that the spread
of synthetic drugs use in the EU has generally stabilised,
upward trends in ecstasy use are still observed in some
regions where cities or holiday resorts are more likely to
attract young European tourists owing to their location
and larger offer of youth-oriented events. More generally,
urban areas where youth cultures have been established
may continue to provide a setting for ‘recreational drugs’
to anchor and develop.
Cross-analysis of qualitative surveys suggests that the
consumption of synthetic drugs has spread beyond the
‘techno scene’ to discotheques, nightclubs and also
private settings. Other settings are also reported. For
example, a 1998 study found that, in Greece, 35 % of
student ecstasy users have used the drug at football
matches.
Behaviours and patterns of use
A growing behaviour trend is not so much the consump-
tion of one particular drug above another, but rather a
tendency to instrument different drugs in relation to needs
and situations.
Changing patterns in youth behaviour have been
highlighted in some Member States as a subject for more
in-depth investigation.
• Most countries underline the phenomenon of quickly
changing patterns among a broad public to experi-
ment and/or combine different substances to get ‘high’
and/or to balance the respective effects.
• In the Netherlands, the phenomenon of ‘ecstasy-
fatigue’ is currently being assessed. The reasons for this
trend may be due to various factors, for example that
there is no logo proof of exact contents or a heightened
awareness (raised through the media) of the adverse
residual effects on mood and feelings. The question as
to whether cocaine plays an alternate role as a basic
(27) Table 7 OL: Provision, utilisation and coverage of syringe exchange programmes (SEPs) for injecting drug users (IDUs) and cover-
age of pharmacies in some European countries, as reported by national focal points, 2000 (online version).
(28) Table 8 OL: Provision of HIV counselling and testing, HIV treatment and HBV vaccination for injecting drug users (IDUs) in some
European countries, as reported by national focal points, 2000 (online version).
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stimulant with regular and known effects is also posed.
The combination of cocaine and alcohol is reputed to
be a ‘good mix’ among experienced users, while the
combination of ecstasy and alcohol is considered more
difficult to manage.
• As far as ecstasy problem users are concerned, some
studies on addiction point out that the addictive
potential of the substance itself may play a lesser role
than the non-chemical and behavioural addiction
patterns associated with it.
All Member States, when drawing up strategies, attach
importance to differentiating between groups of synthetic
drugs users. A first and very broad differentiation of
ecstasy users can be made.
• Excessive users. Even if MDMA has a low dependence
potential, a minority of users show a compulsive
pattern of use — more than once a week, more than
one pill at a time, use of multiple other substances,
intensive party activity throughout the weekend and a
lack of sleep. They are frequently part of a network
where drug use is very common.
• Cautious users, with a less extensive pattern of use.
• Occasional users, with less knowledge and awareness
of possible risks.
Combined use of various substances, licit and illicit, is a
common behaviour pattern among young people with an
outgoing lifestyle (bars, discotheques, ‘rave’ and techno
parties, private parties). Polyuse — mixing or alternating a
large range of substances, synthetics or non-synthetics —
is the main trend, and ‘self-management’ of polyuse in a
changing context is a predominant pattern.
Shifting from one product to another and polyuse patterns
are linked to a certain extent to the availability of different
substances and opportunism plays a role. Personal/in-
group strategies are often mobilised to obtain a particular
substance and group dynamics play an important role.
A distinction should be made between substances which
are believed to be more adapted to the music event itself
and other drugs (such as after-dance drugs or not-dance
drugs) or substances experimented within an initiation
circle led by experienced users with at least some
What are synthetic drugs?
The term ‘synthetic drug’ strictly refers to psychoactive
substances that are manufactured through a chemical
process in which the essential psychoactive constituents
are not derived from naturally occurring substances.  The
term ’synthetic drug’ began to be used synonymously
with dance or recreational drugs following the
emergence of the synthetic drug ecstasy (MDMA) and
other ring-substituted amphetamines in the recreational
dance drug scene, although non-synthetic drugs, such as
cannabis, cocaine and magic mushrooms, are also
consumed in these settings. Synthetic drugs with long
histories of illicit use include amphetamines and lysergic
acid diethylamide (LSD), while ecstasy (MDMA) and
other drugs listed in Alexander Shulgin’s Pihkal list (1)
have much shorter histories of illicit use. There is growing
global concern about the potential manufacture of other
and newer synthetic drugs sold as an alternative to
MDMA, or added to MDMA tablets. The ease with which
many ‘synthetic drugs’ can be manufactured constitutes a
challenge to efforts to control supply, as laboratories can
be set up and moved with relative ease. 
Some synthetic drugs, not all, have hallucinogenic effects
and may be either stimulants or depressants of the central
nervous system (CNS), the latter being the case for GHB.
There are also synthetic opiates, such as methadone,
pethidine (MPPP, MPTP), fentanyl, 3-methyl-fentanyl, etc.
‘Designer drugs’ are chemical analogues of controlled
drugs. Illegal producers modify slightly the molecular
structure of a prohibited substance in order to obtain
similar or stronger pharmacological effects, thereby
avoiding prosecution. The EU joint action on new
synthetic drugs (see box on page 46) was launched in
June 1997 with the purpose of preventing and/or limiting
the extension of such practices.
Amphetamines are synthetic drugs. They may be injected,
as is the case in Sweden and Finland, or taken in tablet or
powder form. Amphetamines are frequently mixed in
ecstasy-like tablets with MDMA or ecstasy analogues.
Methamphetamines are methyl derivatives of ampheta-
mines (mainly but not exclusively of the unsubstituted-
ring type). They include ‘methedrine’ as well as ‘crystal’
and ‘ice’ which are forms that can be smoked. 
(1) A. and A. Shulgin (1991), Pihkal: A chemical love story,
Transform Press.
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empirical knowledge about dosages and side-effects. For
a limited number of synthetic drugs, the lack of such an
environment could possibly present greater risks.
Availability of substances
MDMA is still the favoured product of the ecstasy market
and appears under numerous different logos and many
different names. For example, the German Criminal
Police Laboratory in Wiesbaden which monitored tablets
stamped with a ‘Mitsubishi’ three diamond-triangle logo
has issued a list of more than 200 different end-products.
Overdosed MDMA tablets were detected through
seizures and toxicological analysis or through on-site
pill testing by prevention teams at music events, allow-
ing information on their characteristics to be rapidly
disseminated to all EU countries through the EU early
warning system.
A trend that needs to be monitored closely is the increas-
ing number of psychotropic medicines such as ketamine,
diverted from legitimate sources.
Lower purity and availability is noted for amphetamine (or
‘speed’ — amphetamine sulphate). Scandinavian countries
are still the main market for injected amphetamine and the
United Kingdom for non-injected amphetamine.
The average consumption of methamphetamines is
still very limited in the EU. However, according to
Europol (29), evidence of production (laboratories
dismantled) has been confirmed for Germany and the
Netherlands. Estonia and especially the Czech Republic
have also been involved in production and trafficking.
Methamphetamine, probably produced in the Czech
Republic has progressively replaced amphetamine for
consumers in Bavaria and Saxony, two bordering German
Länder. Several seizures of this substance were reported
to Europol in 1999 by the law-enforcement agencies of
Finland, Sweden, Germany and the Netherlands.
Although still present on the drug scene, the market for
LSD and other hallucinogens has stabilised or levelled off
in most EU countries.
Treatment data
Treatment data, as an indication of the level of problem
drug use, provides very little coverage for synthetic drugs
with the exception of injected amphetamine. Ecstasy is
scarcely ever recorded as the primary drug in demand for
treatment, the patients typically being polydrug users. The
higher level of treatment demand for amphetamines as
primary drug with respect to Sweden and Finland can be
explained by the historical pattern of injecting ampheta-
mine sulphate in these countries.
In the Netherlands, the introduction of a specific entry for
ecstasy use in 1994 has resulted in a complete registra-
tion in 1995 in the outpatient care system. Figures show a
declining trend in treatment demand for ecstasy since
1997, taking into account the apparent initial increase in
the two preceding years and this may be due — at least in
part — to improved registration. Still, ecstasy makes up
no more than 1 % of all drug clients (3.1 % for ampheta-
mines). In 1999, the number of clients reporting ecstasy
as secondary drug was twice the number of clients with
ecstasy as main drug, a figure consistent with the fact that
ecstasy users are typically polyusers.
Health risks
Although rare and poorly documented, there are possi-
ble acute effects of ecstasy-type substances, especially
when taken with other licit or illicit drugs (such as GHB
and alcohol), when mixed with other drugs with less
potential of acute adverse effects, or when tablets are
strongly overdosed and/or taken repeatedly over a short
period of time.
Clinicians emphasise the role of risk behaviour (such as
the compulsive search for a ‘high’ and ignorance of
composition and/or effects) rather than the toxicity of a
particular substance isolated from its context and
patterns of use. Personal health background may also be
a determinant.
In most cases, poly-intoxication is the diagnosis, it being
impossible to point to one substance above another.
In order to understand the nature and possible long-
term risks and neuro-psychic aspects which frequently
Ecstasy and amphetamine clients in outpatient
addiction care in the Netherlands
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(29) Europol  2000 report, The Hague, the Netherlands.
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emerge in acute intoxication cases, the priority for
clinicians is now the follow-up of non-fatal intoxica-
tions among young users of ecstasy (mostly mixed with
other drugs).
Long-term use may produce adverse effects. Reversible
and/or non-reversible effects on the brain are still
under discussion. In heavy ecstasy users, there is
increasing evidence of damage to serotonergic
neurons. Clinical implications indicate cognitive
deficits but research projects in this area (under way in
the United Kingdom and United States) are still few
and far between.
Related deaths
Since outreach and other prevention measures have been
undertaken at techno/house events and parties, a
decrease in fatal incidents has been observed compared
with the early nineties, at least in countries where
emergency cases were recorded and documented.
Apparent overdose by amphetamine or phenyl-
propanolamine derivatives, where these derivatives were
considered as the main cause of death, were attributed to
50 % of fatal cases in the Netherlands during the period
1994–97. In the remaining cases, amphetamine deriva-
tives were present but death was attributed to other drugs
and/or alcohol or unknown causes.
One new synthetic drug, 4-methylthioamphetamine (4-
MTA, with the street name ‘flatliner’) has been implicated
in a number of deaths in the EU (four deaths in the United
Kingdom, one in the Netherlands). Another ‘new’
synthetic drug, GHB (gamma-hydrobuxyrate), has also
been linked to some deaths, generally in association with
alcohol and/or other drugs. These two substances have
been subject to monitoring and risk assessment in the
framework of the EU joint action on new synthetic drugs
(see box on page 46).
Responses
Responses to synthetic drugs are organised at different
levels of intervention.
Primary prevention concentrates on providing informa-
tion on synthetic drugs and is usually carried out through
public campaigns and in-school interventions.
Harm-reduction/outreach activities in recreational
settings consist of chill-out rooms, pill testing, informa-
tion leaflets and on-site desks. There are also ‘auto-
support’ initiatives in the techno scene which aim to
include information on synthetic drugs and associated
substances in a range of music-oriented activities.
Information among users about the risks of mixing
substances (especially the risk of alcohol) and the early
detection of new risk groups among young people is now
considered crucial. 
The aim of quick health reponses is to provide targeted
prevention information which allows professionals in
emergency rooms and poison units, GPs, field health
workers, etc. to detect and respond better to cases of
acute intoxication. In France, since 1998, Médecins du
monde has ensured medical stand-by assistance at raves
and other ‘free-parties’. Difficulties include the lack of
clinically related literature on acute intoxication
episodes, and the impossibility of referring to the individ-
ual’s medical history.
Even if they have a less problematic drug-use profile,
‘new’ drug users (new or experienced users not known by
treatment services) may be provided with improved infor-
mation on how to identify signs of problem drug use and
the need for assistance. Self-perception of one’s state of
health, awareness of losing control of ‘self-managed’ use
and knowledge about access to counselling services are
possible indicators to be combined with preventive
outreach actions. However, the lack of diversity and/or
relevance of existing treatment offer may limit the effect
of such efforts.
Fig. 32 Number of ecstasy seizures
in 1999
Quantities in number of tablets are provided in brackets
Above 6 000
3 000–6 000
1 000–3 000
Below 1 000
1 064
(229 092)
649
(1 860 402)
2 883
(1 470 507)
Belgium &
Luxembourg
2 163
(489 566)(1)
10
(357)
1 995
(357 649)
n.a.
(2 815)
160
(73 250)
159
(17 665)
n.a.
(3 849 645)
197
(26 117)
215
(31 129)
6 438
(6 323 469)
73
(31 319)
n.a.
(288 403)
NB: n.a. = data not available.
(1) Includes also amphetamine tablets seized.
Differences that may be found between these data and those published by 
Europol are due to differences in reporting dates.
Sources: Reitox national focal points, 2000.
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Supply reduction
According to Europol (Annual report 2000), the
Netherlands is still the primary country for the production
and export of ecstasy: 36 production sites were identified
in 1999. During the same year, four laboratories were
dismantled in Belgium, two in Spain, and one in
Germany. One of the largest amphetamine laboratories
ever found was dismantled in Greece in February 2000.
Production and export also involve a number of the east
European countries (the Czech Republic, Poland and
Bulgaria) and the Baltic States. 
By way of example, 10 to 20 % of synthetic drugs for
the UK market are manufactured in the United
Kingdom, while the rest are thought to be manufac-
tured on the continent (predominantly the Netherlands
and Belgium) and enter the United Kingdom at Channel
ports or airports.
The average wholesale price (sales per kilogram) for
tablets marketed as ecstasy ranges from EUR 4 to EUR 5
per tablet, with a minimum price of EUR 1 in Portugal
and a maximum price of EUR 13 in Denmark (30). The
average retail price ranges from EUR 4 to EUR 28 per
gram, with a minimum of price of EUR 4 in the
Netherlands and a maximum of EUR 34 in Denmark.
New initiatives and challenges for
policy-making
Synthetic drugs are in the political limelight despite the
limited scientific evidence available in terms of public
health risks. Their high level of use among socially
integrated groups, their role as a reference model within
youth culture and the fact that production and trafficking
are set up in Europe (for both internal and external
markets) exert strong pressure for responsible action by
the EU.
Synthetic substances and their risk assessment are
progressively included in a broader view of changing
patterns and behaviours, subcultures and evolutions. This
has resulted in the following actions:
• setting up efficient communication channels between
all actors involved in rapid-response systems;
• setting up better communication between scientifi-
cally based information and policy responses;
• improving capacity for obtaining specific information
on synthetic drugs and more generally on emerging
trends in drug use through national and local preva-
lence estimates, treatment demand records, also
taking into account the main orientation of treatment
services towards opiates users.
The EU joint action on new synthetic drugs
During the period 1998–2000, the EU joint action
‘early-warning system’ for the rapid collection and
exchange of information on new synthetic drugs
detected a number of substances which appeared on the
illegal market in the European Union. Joint progress
reports summarising the information collected at this
preliminary stage were presented by the EMCDDA and
Europol to the Horizontal Working Party on Drugs of the
Council of the European Union. At a second stage,
following a request by the Council, four of these
substances — MBDB, 4-MTA, GHB and ketamine —
have been subject to a risk assessment by the enlarged
Scientific Committee of the EMCDDA.
On the basis of its risk-assessment report and an opinion
of the European Commission, one new synthetic drug, 4-
MTA, is subject to control measures in all EU Member
States by a Council decision of 13 September 1999.
Other new synthetic drugs, such as PMMA, 2-CT-5 and 2-
CT-7 have recently been detected under the joint action
‘early-warning system’ mechanism and are currently
being monitored jointly by the EMCDDA and Europol, in
close cooperation with the European Commission and
the European Medicines Evaluation Agency (EMEA).
As an instrument to define whether or not a particular
substance should be placed under control at EU level, the
joint action also provides Member States and European
institutions with a regular insight into the context of drug
use in recreational settings and gives early indications on
trafficking trends in synthetic drugs. The risk-assessment
exercises bring sound material to the attention of policy-
makers for their reflection on possible options for a
balanced approach between law enforcement and
preventive measures.
(30) Last data: July 1999. The prices vary within different Member States depending on purity rate, amount purchased and location of
purchase (Source: Europol, annual report 2000).
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The drugs problem in central
and east European countries
This chapter makes use of the recent information made available through the Phare multi-
beneficiary drugs programme. Currently, partnership between the EMCDDA and the
candidate countries is in a transition period during which direct technical cooperation
will be expanded to further develop the institutional basis for national drug information
systems, to consolidate relations and to establish permanent structural links.
Situation and trends
On the whole, the major trends identified in 2000
are confirmed:
• an increase in the percentage of the general popula-
tion, especially schoolchildren who have tried illicit
drugs at least once in their lifetime;
• an increase in demand for treatment, mostly for
opiate dependency;
• change in the patterns of drug use, with imported
heroin increasingly taking the place of locally
produced opiates;
• a spread of drug use from major urban centres to
all regions;
• an increase in the problems and challenges associated
with the trafficking and transit of illicit drugs.
Prevalence and patterns of drug use
According to the data collected by the European school
survey project on alcohol and other drugs (ESPAD) in
1995 and 1999, lifetime experience of illicit drug use
among schoolchildren (15 to 16-year-olds) doubled
during the same period in all central and east European
countries (CEECs), except in the Czech Republic, where
this prevalence was already quite high and increased one
and a half times (see Figure 33).
This increase reflects mostly the rise in the use of
cannabis, which remains the most common drug used
among teenagers.
In parallel, a significant but smaller increase, has been
detected in the use of drugs like ecstasy, amphetamines,
or LSD (Table 4).
4C h a p t e r
Lifetime experience of any illegal drugs
(all students – ESPAD)
Fig. 33
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However, some data collected at city level or in more
targeted subgroups reveal that the prevalence of synthetic
drugs use may be greater than that suggested by national
figures, although accurate data on the number of users in
the population are not available.
In Lithuania, in the 1999 ESPAD study, lifetime preva-
lence of any illicit drugs among schoolchildren was found
to be at 22.7 % in Vilnius, and at 23.9 % in Klaipeda,
while the national average was 15.5 %.
In the Czech Republic, in a study carried out on the
‘techno’ party scene in Prague during 1998 and 1999,
lifetime prevalence was found to be at 44.5 % for
amphetamines, 35.7 % for ecstasy and 47.7 % for hallu-
cinogens (compared respectively with 5 %, 4 % and
7 % in the ESPAD study carried out at national level).
Treatment demand
The demand for treatment — mostly for opiate use — still
appears to be increasing (Table 5).
However, it should be underlined that patterns of
consumption, as well as the problem substances
themselves, may differ substantially from one country or
one region to another.
Availability
Major seizures along the Balkan route and in central
Europe in 1999 and 2000 confirm the role of the region in
the transit and storage of heroin. It is notable that the total
amount of heroin seized by the Bulgarian authorities in
2000 is 2 079 kilograms, which is more than the total
amount seized during the preceding six years. Most of
these seizures are made at the main checkpoint with
Turkey. Corresponding increases cannot be seen
elsewhere on the Balkan route. However, as heroin
consumption rises, it seems that the CEEC countries are
increasingly becoming targets as well.
Central and eastern Europe continues to be a transit
region for cannabis destined for the EU Member States. In
2000, seizures are reported from most of the countries.
Studies show that cannabis is the most widely used drug
in the CEECs and there are suggestions that, as is the case
in the EU, there has been a noticeable increase not only
in illegal traffic but also in the cultivation of cannabis in
the region.
The transit role of central and eastern Europe in cocaine
trafficking seems to have developed further during 1999
and 2000. Major cocaine seizures involved Hungary, the
Czech Republic and Romania. Yet consumption seems to
be limited to particular segments of the population, the
size of which is difficult to estimate through existing
monitoring systems.
Popularity of synthetic drugs is growing among young
people (Table 4) and there are worrying signs that an
increased number of juveniles are involved in the traffick-
ing and selling of drugs. The production of synthetic drugs
has increased and its consumption influences the life of
more and more young people. Illegal laboratories
producing amphetamines exist in most of the CEECs, and
precursors for production purposes are being smuggled
from other CEECs, the EU or third countries.
Illegal laboratories have been dismantled in almost all of
the countries in the region. In particular, Poland, the
Czech Republic, Hungary, Bulgaria and the Baltic States
seem to be major producers. For example, despite the
Table 4
Lifetimeexperienceofecstasy,amphetaminesand
LSD use among schoolchildren, ESPAD 1995–99
1995 1999 1995 1999 1995 1999
Bulgaria – 1 – 1 – 1
Czech Republic 0 4 2 5 2 7
Estonia 0 3 0 7 1 3
Former Yugoslav 
Republic of Macedonia – 1 – 0 – 1
Hungary 1 3 0 2 1 4
Latvia 0 6 0 4 0 4
Lithuania 0 4 0 2 0 2
Poland 0 3 2 7 1 5
Romania – 0 – 0 – 0
Slovak Republic – 2 0 1 0 4
Slovenia 1 4 0 1 1 3
Ecstasy Amphetamines LSD
NB: n.a. = data not available.
(1) First demand for treatment.
(2) Number of treatment cases (non harmonised indicator). 
(3) Number of registered users.
Number of demands for treatment in the CEECs
since 1993 (all demands)
Table 5
1993 1994 1995 1996 1997 1998 1999
Albania n.a. n.a. 27 63 334 523 615
Bulgaria n.a. n.a. 254 449 582 974 1071
Czech Republic(1) n.a. n.a. 2 470 3 252 3 132 3 858 3 889
Estonia n.a. 246 366 755 n.a. n.a. n.a
FYROM 82 116 242 301 431 n.a. n.a.
Hungary(2) n.a. 2 806 3 263 4 233 7 945 8 957 12 765
Latvia n.a. 781 804 904 992 1 080 1 512
Lithuania(3) n.a. n.a. n.a. 1 804 2 871 2 862 3 082
Poland 3 783 4 107 4 223 4 772 n.a. n.a. n.a.
Romania n.a. n.a. n.a. n.a. 646 650 n.a.
Slovakia n.a. 1 189 1 239 1 594 2 074 2 199 2 236
Slovenia(1) 141 187 125 309 n.a. n.a. n.a.
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dismantling of seven laboratories in Poland in early 2000,
it is estimated that at least the same number could still be
operational. The worldwide prevalence of ecstasy use has
led to the export of the drug from the EU to markets in
central and eastern Europe. Law-enforcement agencies
report that a significant proportion of the ecstasy used in
the CEECs originates in the Netherlands.
Policy and institutional responses
to the drug phenomenon
Since the mid-1990s, drug policy and strategy develop-
ments in the central and east European countries (similarly
to the EU Member States) have two main roots: firstly,
the changing nature of the drug phenomenon which
increasingly affects broader segments of society; and
secondly, the multidimensional character of the problem
which demands a nationally coordinated multidiscipli-
nary response.The actions of various international organi-
sations, notably the European Commission, have provided
a catalyst for the development of national responses to the
drug phenomenon.
Within this context, the central and east European
countries have taken substantial steps to developing the
appropriate legislative measures and administrative and
coordination structures. In addition, as part of the
process of EU enlargement, under the pre-accession
strategy, the 10 candidate CEECs (31) have adjusted or
reoriented their drug control actions towards adopting
and implementing the acquis communautaire. A similar
process is taking place in the Former Yugoslav Republic
of Macedonia despite the fact that it is not yet an appli-
cant to join the EU.
Legislation
All candidate CEECs have signed and ratified the three
UN drug control conventions — these being regarded as
inseparable from achieving the objectives of the EU
drugs strategy. Estonia, in 2000, was the most recent
country to ratify the 1988 ‘UN convention against Illicit
traffic in narcotic drugs and psychotropic substances’.
All candidate CEECs have signed and ratified the 1990
Council of Europe Convention on Laundering, Search,
Seizure and Confiscation of the Proceeds of Crime
(Strasbourg Convention).
The process of adopting national legislation varies in its
intensity and approach throughout the region, from the
adoption of several laws addressing specific drug-related
issues — such as is the case of Hungary — to the concept
of a single wide-ranging ‘umbrella-type’ drug law — for
example, the 1997 Law on Counteracting Drug Addiction
in Poland. The latter was amended in 2000 to make more
restrictive the provisions regarding the possession of small
quantities of drugs and also to strengthen the role of
demand reduction. A similar type of law has recently
been passed in Bulgaria (1999). In the last two years,
Slovenia adopted three major drug laws: on production
and trade in illicit drugs (1999); on precursors for illicit
drugs (2000); and a law dealing exclusively with the
prevention of drug consumption, treatment and the
reintegration of drug addicts (1999). The 2000 Romanian
Law on Combating Illicit Drugs Trafficking and
Consumption is rather brief and will probably be
followed up by a substantial number of secondary legisla-
tive measures. All candidate countries have adopted
specific precursors control legislation, largely compatible
with EU regulations. For example, in 2000, laws were
passed in Slovenia and Slovakia, as well as regulations on
precursors introduced in Lithuania, Poland and Bulgaria.
National coordination
In line with the new legislation, the national coordination
and decision-making structures in most of the candidate
CEECs have undergone significant changes in 1999 and
2000. In 1999, the Czech National Drug Commission
approved the statute of its consulting body — the board of
representatives of ministries — and tasked it with the
preparation of a new national strategy. The Hungarian
Drugs Coordination Commission was reformed so as to
Slovenian drug law
The Slovenian Law on the Prevention of the Use of Illicit
Drugs and Dealing with Consumers of Illicit Drugs
(1999), besides setting out measures for preventing the
use of illicit drugs, also sets out measures on: information,
medical, educational, and consulting activities; medical
treatment; social security services and programmes for
resolving social problems related to the consumption of
illicit drugs; and for monitoring the consumption of illicit
drugs. The law addresses, among others, the need for the
involvement of non-governmental organisations and the
coordination of their activities with the national
programme. It is foreseen that the funds for co-financing
the implementation of prevention programmes and for
monitoring consumption will be provided from the
national budget.
(31) The following CEECs are candidates to join the EU: Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland,
Romania, Slovakia and Slovenia.
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strengthen its mandate and operational capacity. The new
laws passed in Slovenia and Bulgaria firmly established
inter-ministerial coordinating bodies in these countries
enhancing their role through the creation of permanent
support structures — the Governmental Drugs Office and
the National Drug Council Secretariat respectively —
similar to those in the Czech Republic and Slovakia. The
Romanian ‘inter-ministerial committee for the fight
against drugs’ was established in 1999 and is yet to
become fully operational, whereas in Poland such a body
has not been functioning since 1998. Most of this
reorganising has successfully enabled the countries to set
up a structure with a view to meeting the specific needs of
a changing society and the problems it is confronted with.
The leadership of the inter-ministerial coordinating body
is usually ensured by one of the participating ministries.
In most of the countries this is a ministry dealing with
social matters — the Ministry of Health in Bulgaria,
Lithuania and Slovenia, the Ministry of Social Affairs in
Estonia, and the Ministry of Youth and Sports in Hungary.
In other countries, it falls directly under the government’s
office — chaired by the Prime Minister in the Czech
Republic and the Deputy Prime Minister in Slovakia — or
lies with the Ministry of Interior, as is the case in Latvia. In
Romania, the inter-ministerial body is by definition ‘under
the leadership’ of the Prime Minister but its work is organ-
ised by the Ministry of the Interior.
For the purpose of implementing and coordinating
national policy at local level, local drug commissions
were set up in the Czech Republic in 1999 and in
Bulgaria in 2000, the establishment of municipal multi-
disciplinary drug councils was initiated. These are similar
to the regional and district drug commissions established
in Slovakia in 1997.
National strategies and action plans
In countries where the inter-ministerial drugs body is well
positioned, such as in the Czech Republic and Slovakia,
multidisciplinary national strategies are elaborated and
implemented in a more consistent manner. The Czech
Republic, for example, has adopted its third consecutive
national strategy. The process of elaborating strategic
documents and action plans intensified in 1999 and
2000, and national drug strategies were adopted in
Slovakia (1999), Poland (1999), Hungary (2000) and the
Czech Republic (2000).
The Estonian ‘Alcoholism and drug abuse prevention
programme’ (1997–2007), the Latvian ‘Drug control and
drug abuse prevention master plan’ (1999–2003) and the
Lithuanian ‘National drug control and drug prevention
programme’ (1999–2003) are under revision. In Slovenia,
a ‘National programme for prevention of drug misuse’
adopted in 1992 has been implemented over the past
years. A new programme is due to be adopted based on
recent legislation. Comprehensive drug control and
prevention strategies are still to be adopted in Romania
and Bulgaria. The latter has adopted a national
programme for prevention treatment and rehabilitation of
drug addicts for the period 2001–05.
The new strategies demonstrate commitment, in that the
drug problem is acknowledged at the highest political
and executive level. They also provide the basis for multi-
disciplinary programmes. Most of the recently adopted
strategic documents are concrete action plans in
themselves, stating objectives, targets, achievement
indicators, etc., and often securing or bidding for
increased financial resources. The need for improved
drug information and evaluation of the interventions is
increasingly recognised and included as an integral part
of the national actions. The partnership between govern-
mental and non-governmental sectors in policy develop-
ment and programme implementation appears to be
increasingly responding to the individual and collective
needs of the general population as well as to the drug-
using population. It is worth noting that all new strategies
in the candidate countries strive to ensure consistency
between domestic policies and policies and strategies
endorsed at EU level.
Czech Republic
At the end of 2000, the Government of the Czech
Republic adopted a national drug policy strategy 
for 2001–04. The strategy lists 82 specific tasks and
stipulates that all relevant ministries with a mandate in
the drugs field, as well as the regional and district
authorities responsible for drug policy, have the task of
preparing a specific drug action plan for 2001–04 in line
with the strategy. The strategy takes into account the
administrative reorganisation and the creation of larger
administrative and territorial units and provides for
enhanced regional coordination.
Hungary
The national strategy for the suppression of the drug
phenomenon, elaborated by the Ministry of Youth and
Sports, was passed by the Parliament at the end of 2000.
This is the first comprehensive, officially adopted strate-
gic document addressing the drug phenomenon in
Hungary. To justify the ‘target-setting’ multidisciplinary
approach employed, the strategy largely relies on the
analysis of available data and previous national and
international experiences. The strategy identifies long-
(2009), medium- (2002) and short-term objectives and
achievement indicators to monitor progress. It also sets
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out the necessary organisational and financial frame-
work for implementing the actions. The strategy
comprises four main objectives: efficient community and
cooperation capabilities; availability of prevention
measures; access to social work therapy and rehabilita-
tion; and reduction of supply.
Poland
Despite the absence of an inter-ministerial coordination
body, the national programme for counteracting drug
addiction in Poland 1999–2001 was adopted at the end of
1999. In the same vein as the EU action plan on drugs
(2000–04), the programme lists eight objectives designed
to strengthen demand-reduction interventions, to increase
the effectiveness of actions on the reduction of illicit
trafficking in narcotic drugs and psychotropic substances,
as well as measures to reinforce the national coordination
structures and international cooperation. In the area of
demand reduction, the programme pays specific attention
to objectives that are highly compatible with those of the
EU strategy such as preventive activities targeting young
people, the improvement of various measures in rehabilita-
tion and social reintegration, the reduction of health conse-
quences of drug use, etc.The need to evaluate the actions
and to set up monitoring modalities is also addressed.
Slovakia
The national programme for the fight against drugs till
the year 2003 with a prospect to the year 2008 is a
policy document adopted further to the implementation
of the first national programme (1995–99). The
programme strives to achieve a balance between
demand and supply reduction actions through address-
ing four main objectives: primary prevention, treatment
and reintegration; drug supply reduction and law
enforcement in combating drugs; mass-media policy;
and international cooperation, where the preparation
for accession and the need for continuous cooperation
with the EU and its institutions, including the EMCDDA
is seen as a priority. The programme also addresses the
need to implement the decisions of the 20th UN
General Assembly Special Session. The principal
sources of funding for programme activities are the
State health fund mainly for prevention activities, the
anti-drug fund mainly for NGO activities in the field of
rehabilitation and aftercare, and the State budget
mainly for ministries or implementation of projects
defined in the programme.
Money laundering
The majority of the candidate central and east European
countries have implemented anti-money laundering
measures. Almost all of them have established a legal,
institutional and judicial anti-money laundering frame-
work and a financial intelligence unit either became
operational or was further strengthened in the last two
years. Furthermore, most of these units have formally
been accepted as full Egmont Group (32) members and
may thus be considered as both complete in compliance
with the EU standards and practices, and to a large extent
able to fulfil their future obligations towards the EU.
New anti-money laundering legislation came into force
in Romania in 1999 and was passed by the Parliament in
Slovakia and Poland in 2000. In 1999, the Bulgarian Law
on Banks was amended and an amendment to the money
laundering act entered into force in the Czech Republic
in 2000.
Summary
Despite the fact that, in general, the legal and institutional
framework in the CEECs is in place, the overall capacities
to implement the adopted measures effectively, as well as
the resources allocated, remain on the whole limited. The
low operational level of the national coordination mecha-
nisms in some countries obstructs the effectiveness of
policy implementation and there is a deficiency in
regional cooperation. In most countries, this affects the
capacity of the institutions concerned to tackle the
problem and constrains their ability to participate effec-
tively in international cooperation measures designed to
deal with the trans-frontier threats with which both the
CEECs and the EU are faced. It is therefore essential that
the countries concerned continue to reinforce their
policies, institutions and coordination mechanisms and
allocate the necessary resources to achieve this. To further
boost this process in 2000, the European Commission
allocated an additional EUR 1 million to each candidate
country for the purpose of developing a specific drug
component in their national Phare programmes. Most of
these projects will be developed through twinning with
EU Member States.
(32) The Egmont Group is an informal organisation established in 1995 with the goal of providing a forum for  financial intelligence
units (FIUs) to improve support to their respective national anti-money laundering programmes. Currently 53 FIUs are members of
the group.
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of 12 decentralised agencies set up by the European Union to carry
out specialised technical or scientific work.
‘Established in 1993 and operational since 1995, the Centre’s main goal is
to provide objective, reliable and comparable information at European level
concerning drugs and drug addiction and their consequences’. 
Through the statistical, documentary and technical information it gathers,
analyses and disseminates, the EMCDDA provides its audience — whether
policy-makers, practitioners in the drugs field or European citizens — 
with an overall picture of the drug phenomenon in Europe.
The Centre’s main tasks are:
• collecting and analysing existing data;
• improving data-comparison methods;
• disseminating information; and
• cooperating with European and international organisations 
and with non-EU countries.
The EMCDDA works exclusively in the field of information.
The EMCDDA online
An online, interactive version of the 2001 Annual report is also available 
on the Internet (http://www.emcdda.org). This version provides links to data
sources, reports and background documents used in assembling this report. 
Detailed information on drug use in Europe, downloadable publications in
all 11 official EU languages, links to specialised drug-information centres in
Europe and beyond, and free access to specialised databases can all be
found on the EMCDDA website. 
